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Bacterial endotoxin stimulates macrophages / monocytes to release various cytokines 
early (e.g., TNF-α, IL-1β, and IFN-γ) and late (HMGB-1) which then mediate sepsis 
(or endotoxemia). HMGB1 recently discovered as late mediator of sepsis, is now seen 
as one of main mediator of sepsis lethality and prompting investigations for 
development of new drugs. Present study was undertaken to screen some novel target 
for ameliorating HMGB1 release and investigate their effect in mice model of 
endotoxemia. 
Here we demonstrate that psychosine increases the HMGB1 in primary peritoneal 
macrophage cells. The psychosine induced HMGB1 may have some interesting role 
in pathobiology of Krabbe disease. 
Aloe-emodin was seen to abrogate HMGB1 release dose dependently in both RAW 
264.7 cells and primary peritoneal macrophage cells. The aloe-emodin was observed 
to attenuate the release of pro-inflammatory cytokines (TNF-α, IL1β) and LPS –
induced oxidative stress markers iNOS, HO-1. The aloe-emodin showed protective 
effect in endotoxemia rescuing mice from endotoxemia lethality. Aloe-emodin also 
decreased the systemic accumulation of proinflammatory mediators (TNF-α, IL1-β) 
within hours in endotoxemic mice. Endotoxemia induced multi-organ dysfunction 
was also ameliorated by aloe-emodin treatment depicted by serum biochemistry 
(ALT, ALP, BUN and creatinine) and histopathology of lung, liver and kidney. The 
neutrophil infiltration was also reduced in lung tissues of aloe-emodin treated mice.
The inhibition of HMGB1 release by aloe-emodin and rescue of endotoxemic mice 
makes aloe-emodin a potential candidate for sepsis therapy. 
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Sepsis is a clinical condition caused by the body's systemic response to an acute 
infection, which can develop into severe sepsis, which is accompanied by single/
multiple organ failure or dysfunction, leading to patient’s death. It is a major cause of 
mortality, killing large number of people (1,400 people approx) worldwide every day 
(Bone et al., 1992). Despite recent advances in intensive care and antibiotic therapy, 
sepsis still happens to be the most common cause of death in the intensive care units.
The pathogenesis of sepsis is attributable to dysregulated systemic inflammatory 
responses characterized by excessive accumulation of various proinflammatory 
mediators such as tumour necrosis factor- α (TNF-α), interleukin (IL)-1 (Dinarello 
and Thompson, 1991), interferon (IFN)-γ (Yin et al., 2005), and nitric oxide (Fink and 
Payen, 1996; Vincent et al., 2000). However inhibition of any of these mediators 
showed no significant relief in amelioration of sepis. Recently it was seen that high 
mobility group box 1 (HMGB1), a ubiquitous protein, is released by activated 
macrophages/ monocytes (Rendon-Mitchell et al., 2003; Wang et al., 1999a), and 
functions as a late mediator of lethal endotoxemia and sepsis (Li et al., 2007; Yang et 
al., 2004).  Circulating HMGB1 levels are elevated in a delayed fashion (after 16–32 
h) in endotoxemic and septic mice (Yang et al., 2004), and in patients with sepsis 
(Angus et al., 2007) which gives HMGB1 more wider window for therapy than other 
cytokines. Recent research has shown that anti-HMGB1 antibodies or inhibitors  
significantly protect mice against LPS-induced acute tissue injury (Abraham et al., 
2000; Ueno et al., 2004), and lethal endotoxemia (Chen et al., 2005; Ulloa et al., 
2002). It is therefore important to search for other agents capable of inhibiting 
HMGB1 and investigate their effect in sepsis.
1.1 HMGB1
High mobility group box 1 (HMGB1) also referred as amphoterin was described over 
three decades ago as a 30 kDa protein which was first co-purified from nuclei with 
histones. It was termed as ‘high mobility group 1’ (HMG-1) protein because of  rapid 
migration in electrophoretic gels, later renamed to HMGB1 by nomenclature (Bustin, 
2001). HMGB1 is an abundant non histone protein and is produced by nearly all cell 
types, however cellular levels vary with development and age (Prasad and Thakur, 
1988). Cellular localization studies have revealed that HMGB1 can migrate between 
the cytoplasm and nucleus in a cell cycle-dependent fashion. HMGB1 is a nuclear 
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protein but the location varies in different cells, lymphoid cells contain HMGB1 in 
both cytoplasm and nucleus (Landsman and Bustin, 1993), whereas cells in liver and 
brain tissues contain HMGB1 predominantly in the cytoplasm (Mosevitsky et al., 
1989). Over the years HMGB1 has been studied and besides its originally described 
nuclear functions, additional properties have been revealed. Extracellular HMGB1 
(released in various conditions) induces migration, recruits stem cells, possesses 
antibacterial functions and complexed HMGB1 induces cytokine production
(Andersson and Tracey, 2011).
1.1.1 Structure
HMGB1 is a member of the high mobility group box (HMGB) family of 
chromosomal proteins consists of three proteins, HMGB1, HMGB2, and HMGB3 
sharing a common structure. HMGB1 is highly conserved between species with a 
sequence homology of 99% between the human and rodent forms, and is present in all 
mammalian cells/tissues. HMGB1 comprises a single polypeptide chain of 214 amino 
acids (the gene encodes for 215 amino acids residues but the initial methionine is not 
expressed). HMGB1 is a member of the high-mobility group (HMG) protein 
superfamily which includes HMGB1, HMGB2, HMGB3 and SP100HMG. The amino 
acid sequences within the HMGB family are highly conserved and all members 
consist of three distinct domains. The two DNA-binding elements of HMGB1, 
marked as the A and B boxes respectively, are made up of approximately 80 amino 
acid residues arranged in three alpha helices (Fig 1.1) and are strongly positively 
charged. The A and B boxes (DNA-binding) are followed by a highly acidic 30 amino 
acid tail containing only aspartic and glutamic acids which can interact with and fold
over the HMG boxes and may thereby interfere with their intermolecular activity 
(Bustin, 1999). The positively charged amino acids may be the reason for its 
migration as a 30kDa molecule in SDS-PAGE gels even though HMGB1 has a 
molecular weight of approximately 25kDa. The large number of charged residues (43 
lysines and 9 arginines in the N-terminal DNA binding domains and 36 glutamic 
acids and 20 aspartic acids in the C-terminal acidic tail) gives the protein strong 
bipolar properties. These bipolar features may promote binding to endogenous and 
exogenous components. HMGB1 has an uneven number of cysteines (a feature seen 
in IL-1β and IL-18, which is presumed to form complex with other proteins.
Figure1.1: Domain structure
HMGB1, a 25-kDa protein
positively charged DNA-binding structures) and a negatively charged acidi
glutamic and aspartic acid)
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of HMGB1 and post-translational modifications
of 215 amino acids. HMGB1 has three domains A box, B box (which are 
c tail (composed of 30 
(Andersson and Tracey, 2011).
. Structure of human
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1.1.2 Post-translational modifications
Besides its native form HMGB1 can exist in several different forms or conformations 
generated through post-translational modifications. HMGB1 actively secreted from 
monocytes can be acetylated in all positions, while protein derived from necrotic cells 
can be acetylated on lysines at positions 2 and 11, segments 27-43 and 178-184 are 
affected particulary, yielding 10 isoforms (at least) of the protein (Bonaldi et al., 
2003). These two positively charged segments act as nuclear localization signals 
(NLSs) and neutralization of these NLSs results in relocation of HMGB1 from the 
nucleus into the cytoplasm. Moreover, phosphorylated HMGB1 is also translocated 
into the cytoplasm and prevented from reentering the nucleus. However, 
phosphorylated HMGB1 has not been demonstrated extracellularly (Youn and Shin, 
2006). Lastly, mono-methylation of HMGB1 on lysine 42 can occur in neutrophils. 
This methylated HMGB1 can be both relocated into the cytoplasm and secreted (Ito et 
al., 2007). All these modifications diminish HMGB1-chromatin interactions but it is 
not clear whether they are required for lysosomal and plasma membrane passage. 
HMGB1 from metabolically stressed cells can also be translocated to the cytoplasm 
without undergoing acetylation or any other known modification (Hamada et al., 
2008).
1.1.3 HMGB1 as Nuclear protein
In the nucleus, HMGB1 plays an important role in transcription regulation, modifying 
the structure of DNA and stabilizing nucleosomes (Bianchi and Beltrame, 2000; 
Bustin, 1999). HMGB1 binds the minor groove of DNA without sequence specificity 
and induces bends, but has a preference for binding sharply bent structures (Bianchi et 
al., 1989). This binding of HMGB1 to DNA facilitates physical interactions between 
DNA and transcription factors, including p53, homeobox-containing proteins, steroid 
hormone receptors and recombination activating gene 1/2 (RAG1/2) proteins which 
are needed for VDJ recombination in T and B lymphocytes (Brickman et al., 1999; 
Mouri et al., 2008). There is one intriguing report about HMGB1 transactivating the 
human IL1-β gene promoter through association with an Ets transcription factor 
(Mouri et al., 2008). There is also one report demonstrating that HMGB1 may directly 
bind to the RRS sequence in the TNF promoter in osteoclasts to activate TNF 
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transcription (Yamoah et al., 2008). Binding of HMGB1 to undamaged DNA is a 
rapid and transient process, while HMGB1 binds tightly to sites of distorted DNA 
(Agresti et al., 2003). HMGB1 constantly shuttles within the nucleus and between the 
nuclear and cytoplasmic compartments (Bustin and Neihart, 1979). HMGB1 has two 
nuclear localisation signals that direct the protein to the nucleus and can in addition 
bind to calmodulin which also can target HMGB1 to the nucleus (Bonaldi et al., 2003; 
Hanover et al., 2007; Youn and Shin, 2006). Export of HMGB1 from the nucleus to 
the cytoplasm is independent of protein synthesis and is mediated by the chromosome 
region maintenance 1 protein (CRM1)(Tang et al., 2007; Youn and Shin, 2006). The 
nuclear function of HMGB1 has been demonstrated to be essential to life since 
HMGB1 knockout mice die 24-48 hours after birth due to hypoglycemia (Calogero et 
al., 1999). Phenotypic features include ruffled, small size and disorganised fur, 
absence of fat and long hind paws. Cells lines deficient in HMGB1 have an abnormal 
gene expression of different genes such as the glucocorticoid receptors, but display a 
normal growth (Calogero et al., 1999).
1.1.4 Cytoplasmic role of HMGB1
HMGB1 plays an important role in migration, interaction with RAGE mediating 
cellular neurite outgrowth and tumor formation (Huttunen et al., 2002a; Rauvala and 
Pihlaskari, 1987). HMGB1 added to normal and dystrophic mouse muscles attracts 
mesoangioblasts, further supporting a role for HMGB1 as a chemoattractant (Palumbo
et al., 2004). In addition, HMGB1 promotes angiogenesis, the process leading to 
formation of new blood vessels during development, growth, tissue repair and tumor 
growth (Chavakis et al., 2007; Mitola et al., 2006; Schlueter et al., 2005). HMGB1
have been placed in the antibacterial barrier defence system, as HMGB1 in purified 
form (isolated from human adenoid glands) eliminates bacteria within a few minutes 
in cultures (Zetterstrom et al., 2002).
1.1.5 Release of HMGB1 
HMGB1 is constitutively expressed in quiescent cells and commonly stored in the 
nucleus, because it contains two lysine-rich nuclear localization sequences that direct 
the protein to the nucleus (Bonaldi et al., 2003). HMGB1 release into extracellular 
milieu is a prerequisite to exert its inflammatory effects. Levels of HMGB1 
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significantly increase in serum of patients with sepsis (Wang et al., 1999a). In healthy 
animals and normal human subjects, HMGB1 is present at an undetectable plasma 
level of 5 ng/ml, but HMGB1 increase to an average of 25.2 and 83.7 ng/ml in 
survivors and non-survivors in septic patients, respectively (Wang et al., 1999a). 
Several studies also show after treatment with endotoxin or various proinflammatory 
cytokines such as TNF-α, IL-1β, or IFN-γ that HMGB1 is released from activated 
monocytes/macrophages more than 8 h and reaches a plateau in expression levels 
around 18–24 h (Andersson et al., 2000; Wang et al., 1999a; Wang et al., 1999b; 
Youn et al., 2008). Despite its clinical importance, the exact mechanism of HMGB1 
release has largely remained unknown, but some progress has been made. HMGB1 
can be released from cells in either active or passive way.
1.1.5.1 Active secretion of HMGB1 
Intriguingly, HMGB1 lacks a classic leader peptide and does not travel through the 
endoplasmic reticulum and the Golgi apparatus, but large amounts of HMGB1 are 
released into the extracellular space by activated monocyte/macrophages (Degryse et 
al., 2001). Recent evidences suggest that the secretion of HMGB1 involve at least 
three steps : (a) exit from the nucleus into the cytoplasm, (b) translocation from the 
cytosol into cytoplasmic organelles, and (c) exocytosis (Gardella et al., 2002). 
Macrophages/monocytes activated by endotoxin or various proinflammatory 
cytokines acetylate HMGB1 at lysine-rich nuclear localization sequences, leading to 
translocation of nuclear HMGB1 into cytoplasmic vesicles and subsequent release 
into the extracellular milieu (Bonaldi et al., 2003; Gardella et al., 2002; Nickel, 2003; 
Rendon-Mitchell et al., 2003). LPS and TNF-α stimulate macrophages/monocytes to 
release HMGB1 through different pathways. LPS stimulates macrophages to release 
HMGB1 by hyper-acetylation partly through CD14- and TNF-dependent pathway 
(Chen et al., 2004; Youn and Shin, 2006) and IFN-β-mediated JAK/STAT pathway 
(Kim et al., 2009). Other studies revealed HMGB1 needs to be phosphorylated for 
secretion, and HMGB1 is phosphorylated by the classical protein kinase C(cPKC) and 
is secreted by a calcium-dependent mechanism in LPS-stimulated 
monocytes/macrophages (Oh et al., 2009). However, TNF-α stimulates macrophages 
to secrete HMGB1 through phosphorylation (Wang et al., 1999a; Youn and Shin, 
2006). HMGB1 levels in serum begin to increase in a delayed manner compared with 
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the early mediators of endotoxin such as TNF-α and IL-1β. Studies show HMGB1 is 
secreted from not only activated macrophages and monocytes, but also from NK cells, 
DCs, and endothelial cells, neurons, smooth-muscle cells, osteoclasts, and intestinal 
epithelial cells (Lotze and Tracey, 2005). HMGB1 secretion can be induced in the 
pituicyte in response to IL-1 or TNF-α stimulation (Wang et al., 1999b). Enterocytes 
secret HMGB1 following stimulation with proinflammatory cytokines (Liu et al., 
2006). Hepatocytes also can secrete HMGB1 in hypoxic conditions and involve Toll-
like receptor 4 dependent reactive oxygen species production and calcium-mediated 
signaling (Tsung et al., 2007).
1.1.5.2. Passive release of HMGB1
Not only can cells actively secrete HMGB1 in response to proinflammatory stimuli, 
but cells undergoing unprogrammed cell death can passively release HMGB1 also, 
which aggravate and prolong inflammation (Scaffidi et al., 2002). HMGB1 is bound 
loosely to the chromatin in whole cell cycle (both interphase and mitosis), and is 
leaked into the medium when membrane integrity is lost in necrotic or permeabilized 
cells (Falciola et al., 1997; Kokkola et al., 2002; Muller et al., 2001). Necrotic cells 
from Hmgb1-/- mice have a greatly reduced ability to promote inflammation, proving 
necrotic cells release HMGB1 that mediate inflammation (Kokkola et al., 2002). In 
contrast, apoptotic cells do not release HMGB1 even after undergoing secondary 
necrosis and partial autolysis, and thus fail to trigger inflammation even if not cleared 
promptly by phagocytic cells (Scaffidi et al., 2002). 
In apoptotic cells, HMGB1 is bound tightly to chromatin because HMGB1 is not 
acetylated, and not released into extracellular milieu (Bustin, 2002; Scaffidi et al., 
2002). However, recent studies show that apoptotic cell can passively release 
HMGB1 at least in some cell types and likely occur during late apoptosis (Bell et al., 
2006; Jiang et al., 2007), indicating that the original dichotomy between necrosis and 
apoptosis may be incorrect. Wang and co-workers also found apoptotic cells can 
stimulate macrophages to release HMGB1 in mice with severe sepsis and 
splenectomy protects against sepsis lethality by reducing serum HMGB1 levels 
(Huston et al., 2008; Qin et al., 2006).
Figure 1.2: HMGB1 release
nucleosomes. Extracellular HMGB1 signals through TLR4, TLR2 and RAGE 
activating various pathways involving nuclear factor
activated protein kinase 
bacterial products, such as endotoxin and/
interleukin-1 (IL-1β), tumour
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. HMGB1 is associated loosely and transiently 
-κB (NF-κB) and the mitogen
(p38). HMGB1 is secreted by immune cells and released by 
or pro-inflammatory cytokines, such as 
-necrosis factor (TNF-α) and interferon
with 
-
-γ (IFN-γ). 
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1.1.6 Receptors of HMGB1
The first described receptor for HMGB1 was the receptor for advanced glycation end 
products (RAGE) (Parkkinen et al., 1993). However, since anti-RAGE antibodies 
only partially suppressed the activity of HMGB1 and RAGE-deficient cells were 
shown to still be able to respond to HMGB1 stimulation, RAGE is not believed to be 
the only receptor for HMGB1 (Li et al., 2003). Recently, toll-like receptors (TLR) 2 
and 4 were suggested to interact with HMGB1 (Apetoh et al., 2007; Park et al., 2006; 
Park et al., 2004). RAGE belongs to the immunoglobulin (Ig) superfamily and 
comprises of three extracellular immunoglobulin domains, a single trans-membrane 
segment and a short cytoplasmic tail. RAGE- deficient mice are viable and less 
susceptible to sepsis (Liliensiek et al., 2004). As a pattern recognition receptor it 
interacts with several ligands such as amyloid-β, multiple members of the S100 
protein family and advanced glycation end products (AGEs) (Bierhaus et al., 2005). 
RAGE is only highly constitutively expressed in lung and skin tissues, but can be up-
regulated in almost every tissue (Shirasawa et al., 2004).
Binding of HMGB1 to RAGE has two main consequences: activation of intracellular 
signal transduction through mechanisms involving Cdc42 and Rac, guanosine 
triphosphatases (GTPase) that regulate cell motility and neurite outgrowth, and the 
other pathway activates mitogen-activated protein kinases (MAPKs) and nuclear 
factor kappa B (NF-κB) (Merenmies et al., 1991; Taguchi et al., 2000). In 
macrophages, Caco-2 epithelial cells and neutrophils the MAPKs activated by 
HMGB1-RAGE interaction are ERK1/2, p38 and p42/44 kinases and stress-activated 
protein kinase/c-Jun N-terminal kinase (Huttunen et al., 2002a; Park et al., 2003; 
Sappington et al., 2002). Smooth muscle cell migration mediated by HMGB1 
involves MAPK pathways and a G-protein-coupled receptor (Degryse et al., 2001). 
The only known adaptor molecules binding to the cytoplasmic tail of RAGE are ERK 
1/2 and diaphanous-1 (Ishihara et al., 2003). A soluble isotype splice form called 
sRAGE exists. The function of this isoform is incompletely understood but does 
provide protective effects in many diseases. An HMGB1-dependent activation and 
recruitment of neutrophils has been demonstrated to require interplay between RAGE 
and Mac-1 (Orlova et al., 2007), indicating the ability of HMGB1 to interact with 
other immunostimulatory molecules in order to amplify their activity. HMGB1 has 
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been described, as mentioned above, to be a ligand of TLRs. The binding of HMGB1 
to TLR leads to activation of downstream signalling cascades ultimately leading to 
NFκB nuclear translocation leading to e.g. transcription of inflammatory genes and 
DC maturation (Takeda et al., 2003).
1.1.7 HMGB1 as proinflammatory cytokine 
Several proinflammatory activities of HMGB1 have been revealed from studies of 
isolated cell cultures. A picture has emerged of HMGB1, when released into the 
extracellular milieu show significantly proinflammatory functionality. The HMGB1 
response participates in the mediation of down-stream pathophysiological responses 
in infectious and non-infectious inflammatory diseases characterized by a 
significantly delayed kinetic response relative to TNF and IL-1. 
The first description of a specific proinflammatory cytokine activity mediated by 
HMGB1 was revealed from studies of the biological response of 
monocyte/macrophage cultures to HMGB1 (Andersson et al., 2000). Addition of 
HMGB1 to macrophage cultures significantly stimulates the release of TNF, IL-1, IL-
6 and nitric oxide (Andersson et al., 2000). The stimulation of macrophages occurs at 
extremely low concentrations of HMGB1, indicating that HMGB1 is the most potent 
endogenous stimulator of TNF release yet described. Addition of highly purified 
recombinant HMGB1 to either human monocytes/macrophages, primary murine 
macrophages or macrophages derived from C3H/HeJ mice leads to significant 
increases in TNF release over a 12 h interval. Maximal increases in TNF mRNA are 
not achieved until 8 h, compared with endotoxin stimulation in which TNF mRNA 
levels are typically increased within 30 min. This uniquely delayed kinetic attribute of 
HMGB1 as a proinflammatory stimulus suggests that it occupies a unique position in 
the cytokine cascade and can function in a feed-forward mechanism to promote 
downstream inflammation. HMGB1-mediated signal transduction in 
monocytes/macrophages appears to be partially dependent on interaction with RAGE, 
a membrane receptor for advanced glycation end-products, S100, β-amyloid fibrils 
and HMGB1. Activation of RAGE by ligand is associated with stimulation of signal 
transduction through p21ras, NF-κB, Cdc42, Rac and MAP kinases (Bucciarelli et al., 
2002).
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HMGB1 has shown proinflammatory activities in other cells also. Addition of 
HMGB1 to neutrophils activates the nuclear translocation of NF-κB and stimulates 
the release of proinflammatory cytokines (Park et al., 2003). HMGB1 signal 
transduction in human neutrophils activates the p38 MAP kinase, phosphatidylinositol 
3-kinase/Akt and ERK1/2 pathways. The kinetics of neutrophil activation by HMGB1 
differs significantly to that by endotoxin: neutrophils release TNF within 60 min after 
addition of HMGB1, whereas maximal TNF mRNA levels in endotoxin-stimulated 
neutrophils occur 4 h after addition of LPS (Park et al., 2003). Thus, early neutrophil 
responses to HMGB1 stand in stark contrast to the monocyte/macrophage response to 
HMGB1. In the former case, HMGB1 mediates an acute or early proinflammatory 
response, whereas in the latter case, HMGB1 signaling occurs significantly later or 
downstream compared with classic endotoxin-induced responses.
The proinflammatory activity of HMGB1 on epithelial cells was revealed by adding 
recombinant HMGB1 to cultured human enterocytic monolayers (Sappington et al., 
2002). HMGB1 mediates an increase in epithelial permeability of monolayers that is 
dependent on increased inducible nitric oxide synthase (iNOS) expression. Inhibition 
of signaling through RAGE abrogates approximately 50% of the HMGB1-mediated 
barrier dysfunction in these epithelial cells, suggesting that HMGB1/RAGE signaling 
contributes at least partially to the epithelial responses to HMGB1. Inhibition of nitric 
oxide synthase activity, or scavenging of peroxynitrite, significantly inhibits HMGB1-
induced epithelial barrier failure (Sappington et al., 2002). Systemic administration of 
HMGB1 to mice significantly increases mucosal permeability and bacterial 
translocation to mesenteric lymph nodes, but mice deficient in iNOS are protected 
from HMGB1-mediated barrier dysfunction, indicating that HMGB1 mediates 
epithelial gut barrier failure through increased nitric oxide production.
HMGB1 activates cytoskeleton reorganization in rat smooth-muscle cells, stimulates 
chemotaxis and increases chemokinesis (Degryse et al., 2001). Smooth-muscle cells 
exposed to recombinant HMGB1 develop a polarized morphology that is typical of 
mobile cells. Smooth-muscle cell migration mediated by HMGB1 is abrogated by 
antibodies against RAGE, and is also inhibited by addition of either pertussis toxin or 
the MAP kinase inhibitor PD9805922. In smooth-muscle cells, the HMGB1 A box 
and the HMGB1 B box each stimulated cell migration, suggesting that the 
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proinflammatory and anti-inflammatory activities of these protein domains can be 
disassociated from their effects on stimulating chemotaxis. Significant binding of 
HMGB1 to the surface of smooth-muscle cells occurs in association with expression 
of RAGE on the plasma membrane.
Endothelial cells, which also express RAGE, respond to recombinant HMGB1 and 
exhibit a  time- and dose-dependent increase in expression of vascular cell adhesion 
molecule-1 (VCAM-1), RAGE and intercellular adhesion molecule-1 (ICAM-1)
(Fiuza et al., 2003). Other proinflammatory cellular endothelial responses to HMGB1 
include increased release of TNF, IL-1, IL-8, monocyte chemottractant protein 1 
(MCP-1), plasminogen activator inhibitor-1 and tissue plasminogen activator. Anti-
TNF antibodies partially inhibit the HMGB1-mediated stimulation of endothelial 
cells. HMGB1-mediated signal transduction in these cells is in part dependent on 
activation of MAP kinases, extracellular signal related kinases and Jun N-terminal 
kinases (Fiuza et al., 2003). When considered with the previously discussed data 
indicating that HMGB1 can activate neutrophils, monocytes and smooth-muscle cells, 
it now appears that the release of HMGB1 into the extracellular milieu can drive a 
proinflammatory endothelial immune cell response.
1.2 SEPSIS
Sepsis syndrome has been differently defined over the years and in order to better 
characterise the pathology, various definitions are used.
The definitions currently used are as follows:
 Infection is a pathologic process, occurs when pathogenic or potentially 
pathogenic microorganisms invade normally sterile tissue, body cavity or 
fluid.  
 Sepsis is said to occur when suspected or documented infection is associated 
with systemic inflammatory syndrome signs (any one).
 Severe Sepsis is said to have occurred when sepsis is complicated by pre-
defined organ dysfunction.
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 Septic Shock is said to have occurred when sepsis induced ACF (acute 
circulatory failure) is characterized by persistent arterial hypotension despite 
adequate volume resuscitation and not explained by causes other than sepsis.
Organ dysfunction can be defined as acute lung injury; coagulation abnormalities; 
thrombocytopenia; altered mental status; liver, renal or cardiac failure; 
or hypoperfusion with lactic acidosis.
Sepsis is an aggressive and multifactorial disease state that has been ranked as the 
tenth-leading cause of death in the US (Hoyert et al., 2001). Morbidity and mortality 
remain unacceptably high despite increasing knowledge about the 
pathophysiological pathways and processes involved in sepsis. Mortality rates from 
severe sepsis are on a similar scale to breast, lung and colon cancer, and it is one of 
the leading causes of death in the intensive care unit (ICU) (Bone et al., 1992; Kanji
et al., 2001). Due to its multifactorial and  aggressive nature, sepsis is a rapid killer. 
The mortality rates of septic shock could be as high as 50% or up to 75% on 
longer follow-ups, even with the best treatment available (Angus et al., 2001; Angus
et al., 2006; Balk, 2000; Quartin et al., 1997; Rangel-Frausto et al., 1995; Silva et al., 
2004). Death is common among sepsis patients, with around 30% of patients dying 
within the first month of diagnosis and 50% dying within 6 months (Bernard et al., 
2001; Natanson et al., 1998; Rivers et al., 2001).
1.2.1 Endotoxin and Sepsis: Connection 
Circulating endotoxin appears to be present in most patients who meet classical 
clinical criteria for sepsis (Marshall et al., 2004; Opal et al., 1999), however not all 
(Bates et al., 1998; Danner et al., 1991). This discrepancy reflects, in part, the well-
recognized limitations of the Limulus amebocyte lysate assay for endotoxin in 
protein-containing specimens, but also an important clinical reality: endotoxin is 
present in some, but not all patients with sepsis, as well as in many patients with acute 
life-threatening illnesses that would not meet the criteria for sepsis. Moreover, it does 
not necessarily follow that the simple presence of circulating endotoxin constitutes an 
adequate rationale for its elimination. 
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Endotoxemia has been demonstrated in a variety of clinical settings, including 
following cardiopulmonary bypass (Riddington et al., 1996), in patients with 
congestive heart failure (Niebauer et al., 1999), in chronic renal failure (Goncalves et 
al., 2006), in cirrhosis (Lin et al., 2007) and in patients with a ruptured abdominal 
aortic aneurysm (Roumen et al., 1993). While endotoxemia is prominent in critically 
ill patients with sepsis, it is also detectable in more than half of all ICU patients on the 
day of ICU admission, even though the majority of these patients do not meet sepsis 
criteria (Marshall et al., 2004). 
Endotoxemia is a purely pathologic state, as shown by antiendotoxin therapies, which 
showed reproducible evidence of benefit when they are employed in disease processes 
such as sepsis in which endotoxemia is common. Early studies supported this 
hypothesis. Ziegler and colleagues (Ziegler et al., 1982), for example, showed that 
neutralizing endotoxin with an antiserum resulted in improved survival for patients 
with Gram-negative infections, and particularly for those in shock. A monoclonal 
antibody directed against endotoxin from a mutant strain of Escherichia coli showed 
similar promise of efficacy in a multicenter study of 543 patients (Ziegler et al., 
1991), an effect, however, that was not replicated in a subsequent larger study 
(McCloskey et al., 1994). Similarly the extracorporeal removal of endotoxin using a 
polymyxin B column has shown evidence of efficacy in pooled data from a number of 
small trials that recruited an heterogeneous population of patients (Cruz et al., 2007), 
as well as in a study of patients with severe intra-abdominal infections (Cruz et al.,
2009). There is, however, evidence that neutralization of endotoxemia may not always 
be beneficial. The lack of efficacy apparent in a number of recent studies using a 
variety of approaches to neutralize endotoxin in patients with sepsis (Angus et al., 
2000; Dellinger et al., 2009) may be explained by shortcomings of the intervention, 
suboptimal dosing or a low prevalence of endotoxemia in the target population. 
Elevated levels of circulating endotoxin can cause a syndrome that bears most of the 
features of clinical sepsis , and the acute administration of a large amount can result in 
organ dysfunction. But endotoxemia, rather than sepsis, is the specific therapeutic
target, and the unanswered challenge remains to determine in which patients with 
endotoxemia will intervention be beneficial. 
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1.2.2. LPS and other sepsis triggers
Sepsis can be caused by infection with Gram-positive bacteria, Gram-negative 
bacteria, viruses fungi, or (and particularly Candida). Sepsis may also occur in the 
absence of any detectable bacterial invasion, and in these cases the sepsis is initiated 
and mediated by microbial toxins, particularly Gram-negative bacteria endotoxin 
(lipopolysaccharide), and endogenous cytokine production. Although activation of the 
immune system during microbial invasion is generally protective and to curb 
infection, development of septic shock in a significant number of patients is a 
consequence of a poorly regulated immune response to the offending organism.
The driving force of the immune system is the need to recognize danger, while the 
goal is to respond to the dangers threatening the organism. Anything which 
causes tissue stress or damage is defined as danger by the immune system. PAMPs 
(Pathogen-associated molecular patterns) like LPS, being exogenous molecules 
derived from micro-organisms can activate immune cells. Besides pathogen-
associated molecular patterns, endogenous alarmins can also activate cells like 
macrophages and neutrophils (immune competent cells). Alarmins are 
molecules produced in stressed or damaged tissues in connection with trauma, burn, 
ischaemia, haemorrhage, or other conditions of altered homeostasis like (i.e. high 
mobility group box-1, heat shock proteins, S100 proteins, hyaluran etc.). Danger-
associated molecular patterns (DAMPs) include both PAMPs and alarmins. 
Inflammation is the primary response to DAMP. The activation of immune cells is a 
prerequisite for initiation of inflammation, which includes inflammation inducers, 
sensors, mediators and effectors. Pattern-recognition receptors (PRR) recognize 
both alarmins and PAMP which are conserved motifs expressed by pathogens, but are 
absent in humans. PRR trigger the production of inflammatory mediators which may 
alter the function of tissues and organs. Alarmins induce SIRS but sepsis involves 
suspected or confirmed infection.
A vigorous innate immune response is now recognized as a double-edged sword, with 
a crucial role in defending the host through activation of antimicrobial defences, and 
yet, if left unchecked, the same system contributes to systemic inflammation, tissue 
injury, intravascular coagulation, and death caused by severe sepsis.
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The initiation of the host response during sepsis or tissue injury involves three 
families of pattern recognition receptors (PRRs): 1) toll-like receptors (TLRs); 2) 
nucleotide-oligomerization domain leucine-rich repeat (NOD-LRR) proteins; and 3) 
cytoplasmic caspase activation and recruiting domain helicases such as retinoic-acid-
inducible gene I (RIG-I)-like helicases (RLHs) (Creagh and O'Neill, 2006; Uematsu 
and Akira, 2007). These receptors initiate the regulate the adaptive immune response 
and innate immune response to tissue injury or infection. Gram-positive and Gram-
negative bacteria, parasites, viruses, and fungi all possess a limited number of unique 
cellular constituents, which are not found in vertebrate animals. These elements are 
now referred to as pathogen activated molecular patterns (PAMPs), or more 
appropriately microbial associated molecular patterns, as these molecules are also 
common in commensal and nonpathogenic bacteria (Granucci et al., 2005). pathogen 
activated molecular patterns (PAMPs) bind to pathogen recognition receptors
(PRRs), such as TLRs which are expressed on the surface of host cells (almost all). 
Cytoplasmic pathogen recognition receptors (PRRs) detect invasive intracellular 
pathogens (Liew et al., 2005). The NOD proteins recognize common fragments of 
bacterial peptidoglycan, muramyl dipeptide from peptidoglycan is the ligand for 
NOD2 and diamino-pimelate from Gram-negative bacteria is the ligand for NOD1 in 
the cytosol. The PRRs also recognized damage signals from the release of 
endogenous peptides and glycosaminoglycans from apoptotic or necrotic host cells 
(Akira et al., 2006; Bianchi, 2007; Mollen et al., 2006). 
TLR expression is significantly upregulated in experimental models of sepsis and in 
patients with sepsis (Armstrong et al., 2004; Tsujimoto et al., 2004; Tsujimoto et al., 
2005; Williams et al., 2003). Trauma including thermal injury generates danger-
associated molecular patterns (DAMPs) that augment TLR expression like PAMPs. It 
also primes or initiates the innate immune system for enhanced TLR 
reactivity, resulting in excess LPS-induced mortality (Paterson et al., 2003). 
Multiple positive feedback loops between PAMPs and danger associated molecular 
patterns (DAMps), and their overlapping receptors PRRs, temporally and spatially 
drive these processes. It may also represent the molecular basis for the observation 
that infections, and also nonspecific stress factors, can trigger excessive systemic 
inflammatory response.   
1.2.3. LPS Signaling
LPS is an important
bacteria (outer membrane)
formation and release of a large spectrum of inflammatory mediators which are 
essential for the early innate and subsequent adaptive anti
it can also lead to a fatal septic syndrome if the inflammatory response is amplifi
and uncontrolled (Beutler and Rietschel, 2003
LPS consists of three parts: 
moiety of LPS is the minimal
‘endotoxin principle’. Lipid A is composed of phosphorylated (1,6 linked) D
glucosamine disaccharide that carries upto six acyl residues. Although structurally 
less variable but variations exists in length, position and number of fatty acids. 
Minimal requirement for bioactivity is lipid A of E.coli having 
Gluco-configurated hexosamine residues and 
any of the components results in decrease of the activity. However the requirement 
differs from species and also depends on the subtype of Toll
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Figure 1.3: Recognition of LPS by CD14 and MD-2. LPS initially recognized by LBP, eventually 
leads to formation of TLR4-MD-2-LPS complex via CD14 on membrane, resulting in dimerization of 
TLR4 subunits triggering TLR4 pathway.
LPS is bipolar macromolecule that contains both hydrophobic and hydophillic 
elements. Lipid A core structure contains hydrophobic and repeating polysaccharide 
surface components contain hydrophilic elements. LPS because of its bipolar nature 
forms microaggregates in blood and then interacts with a variety of serum or 
membrane bound lipophilic proteins. Receptors of LPS recognized in human cells are 
CD14-MD2-TLR4 molecules (soluble or membrane-bound), CD11/CD18 molecules 
and scavenger receptors for lipid molecules. Even small quantities of LPS show a 
significant response because of soluble and membrane bound CD14 which potentiate 
the host response (Hoffmann et al., 1999). In human plasma and other body fluids, 
LPS trafficking is facilitated by a hepatically derived, acute phase plasma protein 
known as LBP (LPS-binding protein) (Opal et al., 1994). LBP performs a shuttle 
service picking up polymeric LPS aggregates and transferring LPS monomers to 
CD14. LPS competes with another neutrophil-derived LPS-binding molecule known 
as bactericidal/permeability-increasing protein (BPI). Despite 45% primary amino 
acid sequence homology of BPI with LBP, BPI specifically antagonizes the actions of 
BPI. LBP assists in the delivery of LPS to immune effector cells while BPI inhibits 
LPS delivery to CD14. The relative concentrations of these two LPS-binding proteins 
primarily determine the net effect of LPS release (Levin et al., 2000; Opal et al., 
1994). CD14 is a glycosyl phosphatidylinositol-linked protein found primarily on the 
cell surfaces of myeloid cells. After docking to membrane-bound CD14, LPS 
is delivered to an essential extracellular adaptor protein known as MD2 (Akira et al., 
2006; Lynn et al., 2003; Nagai et al., 2002). This LPS–MD2 complex is 
then presented to the extracellular leucine-rich domain of TLR4 where multimers of 
this complex aggregate on lipid rafts on the cell surface. This series of events 
then triggers a signal to the intracellular space, subsequently activating 
Lipolpolysaccharide-responsive genes. CD14 also binds to bacterial lipopeptides and 
peptidoglycan and delivers these microbial ligands to TLR2 for 
intracellular signaling. 
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LPS induces dimerization of TLR4/MD-2 complex however the mechanism is not so 
clear because TLRs have been refractory to crystallographic analysis. However 
recently Kim et al proposed a model for LPS induced TLR4/MD-2 dimerization. The 
crystal structure (using hybrid LRR technique) of TLR4 as TLR4-MD-2 and TLR4-
MD-2-eritoran complex showed that othe two TLR4 molecules form a ‘‘m’’-shaped 
complex with binding MD-2 in the two hooks. MD-2-eritoran complex failed to 
activate the dimerization of TLR4 but eritoran showed no contact with TLR4. 
Although TLR4-MD-2 still remains to be cocrystallized with its agonist ligand LPS, 
mutational studies however have shown that residues of MD-2 that are not involved in 
direct contact with either LPS or TLR4 play a key role in homodimerization of the 
TLR4-MD-2 complex in the presence of LPS. Lipolpolysaccharide, is thus proposed 
to induce conformational changes in MD-2 that promotes interaction between MD-2 
and the central and/or C-terminal domain of the second TLR4. This model is 
supported by recent studies.
Once TLR4 binds to its LPS ligand two possible pathways of cellular 
activation can occur through either the myeloid differentiation factor 88 (MyD88) or 
the TLR domain adaptor inducing interferon-β, (TRIF) pathway (Beutler and 
Rietschel, 2003). A series of signaling events occur with sequential activation of 
specific tyrosine and threonine/ serine kinases. This signaling cascade ultimately leads 
to ubiquitination, phosphorylation, and degradation of inhibitory κB (IκB) along with 
other transcriptional activators. IκB degradation releases nuclear factor κB (NF-κB) to 
translocate into the nucleus. Clotting elements, complement, other acute phase 
proteins, cytokines, chemokines, and nitric oxide synthase genes have NFκB-binding 
sites at their promoter regions. The uncontrolled release of inflammatory cytokines 
and other inflammatory mediators after LPS exposure contributes to generalized 
inflammation (Calvano et al., 2005; Reitsma et al., 2003; Suntharalingam et al., 
2006).
Figure 1.4: TLR4 Pathway.
of NF-κB, AP-1 and IRF3 via MyD88 
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Dimerization of TLR4 leads to cascade of pathway leading to activation 
dependent and TRIF dependent pathway.
1.2.4. Pathophysiology of sepsis 
Figure 1.5: Pathophysiology of Sepsis/shock
simultaneously activate multiple parallel cascades that contribute to the
Sepsis/shock. The combination of impaired peripheral vascular tone 
and microvascular occlusion leads to inadequate oxygenation, and 
organ failure/dysfunction.
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1.2.4.1. Role of Cytokines 
Cytokines are a key element in the inflammatory response that characterizes sepsis 
and septic shock. They are immunoregulatory peptides with a potent inflammatory or 
anti-inflammatory action, mediating the immune/metabolic response to an 
external noxious stimulus and fueling the transition from sepsis to septic shock, 
multiple organ dysfunction syndrome, and/or multiple organ failure. Synergistic 
interactions between cytokines can cause or attenuate tissue injury (Calandra et al., 
2002; Casey, 2000). Cytokines may be divided into pro-inflammatory (such as 
tumor necrosis factor [TNF-α], IL-1 and IL-8) and anti-inflammatory (such as IL-10). 
An infectious or inflammatory trigger, such as a microbial toxin, stimulates the 
macrophages that produce in response large amounts of TNF-α, IL-1, and IL-6. TNF-
α is one of the most important cytokines involved in the pathophysiology of sepsis 
and is released early in the process of sepsis. TNF-α induced tissue injury is largely 
mediated through neutrophils, that respond by producing superoxide ion, hydrogen 
peroxide, elastase, leukotriene B4, sPLA2, platelet-activating factor (PAF), and 
thromboxane A2 (Aldridge, 2002). IL-1β stimulates the synthesis and release of 
prostaglandins (PGs), collagenases and, elastases promotes transendothelial 
migration of neutrophils and activates endothelial microvascular cells, which respond 
by releasing PAF and IL-8 (both of which are powerful neutrophil-stimulating 
agents). TNF-α and IL-1 are synergistic and share many biological effects in sepsis. 
Their inhibition improves survival and organ function in animal models of sepsis 
(Herbertson et al., 1995). The controversial role of IL-6 is proved by various studies.
Some consider IL-6 as an anti-inflammatory cytokine; however, some studies show 
that IL-6 augments the cytotoxic potential of neutrophils via selective increase of 
elastase release (Johnson et al., 1998). IL-6 formation is attenuated by the production 
of either TNF-α or IL-1. It is possible that IL-6 is toxic only when it is produced with 
other cytokines (synergistic action of cytokines) (Casey, 2000). IL-8, a neutrophil 
chemotactic cytokine, is involved in the process of tissue inflammation (Baggiolini et 
al., 1994), it along with other neutrophil chemotaxins (chemokines), causes an 
activation of the motile apparatus of neutrophils, directional migration, and expression 
of surface adhesion molecules (Baggiolini, 1995; Baggiolini et al., 1994). During the 
course of inflammation, an equal anti-inflammatory response develops. This anti-
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inflammatory response is associated with the production of anti-inflammatory 
cytokines, IL-4, IL-10, and IL-13 which leads to immune depression, and may 
increase the susceptibility to infections(Cavaillon and Annane, 2006). Because of the 
changing roles of cytokines, the pro-inflammatory versus anti-inflammatory 
dichotomy may be an oversimplification of the inflammatory response involved in 
sepsis.
However, migration inhibitory factor (MIF) and high-mobility group box (HMGB)-1 
protein are seeming as two central cytokines in critical illness induced by  sepsis. 
MIF, which was one of the first cytokines to be discovered, has a pivotal role in 
regulating local and systemic inflammatory responses (Calandra and Roger, 
2003). Bacterial exo- and endotoxins, and pro-inflammatory mediators such as IFNγ, 
tumour-necrosis factor (TNF-α), and C5a are strong inducers of MIF secretion by 
leukocytes. MIF functions as a classical pro-inflammatory cytokine and promotes 
innate and adaptive immune responses by activating macrophages and T cells 
(Calandra and Roger, 2003). HMGB1 which is called late mediator of sepsis lethality 
is dicussed later
1.2.4.2. Role of ROS and RNS
Reactive oxygen species (ROS) are highly reactive and partly reduced derivatives of 
molecular oxygen. This family of substances includes superoxide radical anion, 
hydroxyl radical, hydrogen peroxide, and peroxynitrite (Fink, 2002). Reactive 
nitrogen species (RNS) are derivatives of nitrogen and includes nitric oxide and its 
derivatives. RNS and ROS exert several beneficial physiologic functions, such as 
intracellular signaling for growth factors and several cytokines, secondary messengers 
for hormones and redox regulation. Despite their importance and vital role as a 
defense mechanism against invading pathogens, an overwhelming production of RNS 
and ROS or a deficit in antioxidant defenses and oxidant scavenger result in 
oxidative/nitrosative stress, a key step in the deleterious processes in sepsis
(Macdonald et al., 2003; Matejovic et al., 2007). Stimulated neutrophils produce 
ROS and RNS through the nicotinamide adenine dinucleotide phosphate 
oxidase complex, xanthine oxidoreductase & myeloperoxidase and represent a 
defense mechanism against invading microorganisms (Fialkow et al., 2007). 
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Lipopolysaccharide and other proinflammatory mediators activate nicotinamide 
adenine dinucleotide phosphate oxidase to produce superoxide radical (O2 ). In 
aqueous environments, superoxide radical is rapidly catalyzed by superoxide 
dismutase to hydrogen peroxide (H2O2) and hydroxyl radicals. Myeloperoxidase is 
present in neutrophil azurophilic granules produces hypochlorous acid from hydrogen 
peroxide (H2O2) and chloride anion (Cl¯) during respiratory burst. These free radicals 
are highly cytotoxic and are used by neutrophils to kill fungi, bacteria and other 
pathogens. superoxide radical (O2¯) in the presence of nitric oxide, generates 
peroxynitrite (ONOO¯), which is a key player in the pathogenesis of sepsis 
induced organ dysfunction. peroxynitrite (ONOO¯) can cause DNA strand breakage, 
which initiates the activation of DNA repair enzymes like poly (adenine 
dinucleotide phosphate-ribose) polymerase. Poly (adenine dinucleotide phosphate 
ribose) polymerase inhibitors protect against nitrosative and oxidative stress 
induced organ dysfunction in endotoxemia (Cinel et al., 2002; Ozdulger et al., 2002; 
Taner et al., 2001). Recently, the potential role of poly (adenine dinucleotide 
phosphate ribose) polymerase activation has been implicated in the pathogenesis of 
myocardial contractile dysfunction associated with septic shock (Soriano et al., 
2006).  
Nitric oxide plays an essential role in the pathophysiology of septic shock. Full 
expression of inducible nitric oxide synthase is complex requiring TNF-α, IL-1, LPS, 
and probably other regulatory elements. Nitric oxide is the major endothelial-
derived relaxing factor responsible for the vasodilation and systemic hypotension 
observed in septic shock. Within minutes of administration of an inhibitor of nitric 
oxide synthesis, blood pressure in hypotensive patients in septic shock returns toward 
normal levels (Lopez et al., 2004). Nitric oxide also, inhibits a variety of 
key enzymes in the glycolytic pathway, the tricarboxylic acid pathway, DNA repair 
systems, energy-exchange pathways and electron transport pathways. Nitric oxide 
alters the function of many metalloenzymes, carrier proteins, and structural 
proteins. Like many other components of the host inflammatory response, nitric oxide 
may have both positive and negative effects in sepsis. Nitric oxide regulates 
microcirculation to vital organs and contributes to intracellular killing of microbial 
pathogens. However, excessive and prolonged release of nitric oxide results in 
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generalized vasodilatation and refractory septic shock. Nitric oxide continues to be a 
target for therapeutic manipulation in sepsis. Non-selective inhibitors of nitric oxide 
synthase have been shown to improve the hemodynamics of septic patients 
but increased myocardial work loads and worsened the outcome in a placebo-
controlled trial in patients with septic shock (Lopez et al., 2004). 
1.2.5. Multiple organ dysfunctions 
Organ dysfunction is a hallmark of severe sepsis. There is a close relationship 
between the severity of organ dysfunction on admission to an ICU and the probability 
of survival and the risk of death and between the numbers of organs failing. The 
mechanism of organ dysfunction involve widespread fibrin deposition that causes 
microvascular occlusion or blockade. The development of tissue exudates that further 
compromise and decrease appropriate oxygenation and disorders of 
microvascular homeostasis that result from the increase in levels of 
vasoactive substances such as histamine, PAF and prostanoids. Cellular infiltrates, 
particularly that of neutrophils, cause wide spread damage of tissues directly by 
lysosomal enzymes and superoxide-derived free radicals released from these cells. 
TNF-α, IL-1 and other cytokines increase the expression of inducible nitric oxide 
synthase (iNOS), and increased production of nitric oxide causes further vascular 
instability, occlusion and may also contribute to the direct myocardial depression that 
occurs in sepsis (Hotchkiss et al., 1999a; Hotchkiss et al., 1999b; Hotchkiss et al., 
2001). 
The tissue hypoxia that develops in sepsis is reflected in the oxygen debt or 
deficiency, i.e., the difference between oxygen delivery and oxygen 
requirements. Studies show close association between extent of the oxygen debt is 
and the outcome from sepsis, and also seen that strategies designed to optimize 
oxygen delivery to the tissues can improve survival (Nakagawa et al., 2006). In 
addition to hypoxia, cells are also seen to be dysoxic (unable to properly utilize 
available oxygen) in sepsis. This may be another consequence of excess NO
production because impaired mitochondrial respiration have been seen in skeletal 
muscle biopsies from septic patients , which   is inhibited by nitric oxide and 
suggested recently (Docke et al., 1997). Cross-talk between neurohormones and 
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cytokines is the cornerstone of restoration of homoeostasis during stress. Release and 
production of vasopressin and corticotropin-releasing hormone are enhanced 
by circulating TNF-α and interleukins-1, -2 and -6   by locally expressed NO and 
interleukin 1 and by afferent vagal fibers. Also, cortisol synthesis is modulated and 
changed by locally expressed TNF-α and interleukin-6. These up-regulated 
hormones help maintain cellular metabolism, cardiovascular homoeostasis and 
contain foci of inflammation. Impaired endocrine responses to sepsis might result 
from neuronal apoptosis, cytokines, metabolic and ischemic derangements in 
the hypothalamic-pituitary and drug administration or adrenal glands. Deficiencies or 
abnormalities in adrenal gland function and vasopressin production occur in almost 
1/2 and 1/3 of septic shock cases, and contribute to hypotension and/or death. 
1.3. HMGB1 in endotoxemia/sepsis
Studies show extracellular HMGB1 contributes to a variety of pathophysiological 
process, including diabetes (Han et al., 2008), antibacterial activity (Zetterstrom et al., 
2002), smooth-muscle cell chemotaxis (Degryse et al., 2001), cell differentiation 
(Huttunen et al., 2002b; Sparatore et al., 2001), myocardial regeneration (Limana et 
al., 2005), angiogenesis (Mitola et al., 2006), tissue repair (Palumbo et al., 2004) and 
cancer (Huttunen et al., 2002a). In addition, HMGB1 is a potent proinflammatory 
cytokine and associates with a variety of inflammatory diseases, especially sepsis 
(Kokkola et al., 2002; Wang et al., 1999a). 
1.3.1 Role of HMGB1 in endotoxin lethality
Knowledge of HMGB1 biology as a delayed mediator of systemic inflammation has 
altered our understanding about mechanisms of lethality from Gram-negative 
endotoxemia. Administration of lethal doses of endotoxin to mammals activates a 
biphasic cytokine response that can be divided into early and late kinetic profiles. The 
early response include classical proinflammatory cytokine response, with peak levels 
of TNFα, IL-1β and macrophage-inhibiting factor macrophage migration inhibitory 
factor (MIF) occurring within 6 h (or less). HMGB1 release occurs significantly later; 
levels of this late mediator reach a prolonged plateau beginning 18/24 h after the onset 
of endotoxemia (Wang et al., 1999a). This late activity of HMGB1 is a unique kinetic 
response for a proinflammatory cytokine, with significant implications for 
understanding the lag between the onset of endotoxemia and death of the host, which 
occurs significantly later.
Figure 1.6: Delayed release of HMGB1
infection, placing it downstream of an early TNF response.
Administration of HMGB1 to animals in doses that reach the serum levels observed 
during endotoxemia is lethal 
high levels of recombinant HMGB1 develop a sickness syndrome characterized by 
piloerection, decreased mobility, increased somn
Elevated HMGB1 levels significantly increase the sensitivity of animals to endotoxin, 
such that the administration of sublethal doses of HMGB1 concomitantly with 
sublethal doses of endotoxin is lethal 
examination of animals succumbing to HMGB1 toxicity reveals little necrosis or 
inflammation in the tissues of major organs. The necropsy results are rather bland, an 
observation that is quite similar to the necropsy results seen in patients succumbing to 
sepsis (Li et al., 2003)
poisoning is that HMGB1 induces diffuse epithelial 
2002). This is consistent with the pathological evidence, because failure of epithelial 
cells to maintain tight junctions would be difficult to discern histologically. Death 
would occur from fluid and electrolyte shifts secondary to failed maintenance of 
concentration and energy gradients between cells.
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. HMGB1 is released after a significant lag by innate cells in 
(Li et al., 2003; Wang et al., 1999a). Animals exposed to 
olence, weight loss and fever. 
(Wang et al., 1999a). Histopathological
. A plausible mechanism for the cause of death from HMGB1 
dysfunction (Sappington et al., 
Figure 1.7: HMGB1 in sepsis/endotoxemia. 
endotoxemia. HMGB1 activates macrophages, endothelial cells and enterocytes hours after insult or 
infection
1.3.2 Role of HMGB1 in s
The recent focus on the biology of HMGB1 as a mediator of sepsis has provided some 
pathogenic insights. In a standard animal model of sepsis caused by surgical 
perforation of the cecum in rodents (CLP), leading to severe peritonitis and a 
syndrome of lethal sepsis, HMGB1 levels increase in the serum over a 24/48 h period 
after cecal perforation 
Clinical studies reveal that HMGB1 levels are significantly increased in patients with 
severe sepsis (Wang et al.
the patients with severe sepsis extends up to 150 ng/ml, a range that is similar t
pathological range of HMGB1 levels observed in murine sepsis. An important 
question in the field of HMGB1 biology is whether the circulating form of HMGB1 
identified in the serum of patients with sepsis is complexed to carrier proteins or to 
neutralizing receptor fragments. Thus far, reported serum HMGB1 measurements 
have been achieved using Western immunoblotting methods performed under 
denaturing conditions to reveal a 30 kDa band. It is not yet known whether the 
biological activity of HMGB1 in the 
term survival or outcome. The role of HMGB1 in the pathogenesis of human sepsis 
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Effect of HMGB1 on different cells in sepsis or 
epsis
(Yang et al., 2004).
, 1999a). The range of HMGB1 serum levels observed in 
patients with severe sepsis correlates to long
o the 
-
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will have to be defined on the basis of clinical trials using neutralizing anti-HMGB1 
antibodies in humans with severe sepsis. Clinical trials of neutralizing HMGB1 in the 
treatment of sepsis may be in the offing.
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1.4. Targeting HMGB1 in sepsis 
1.4.1 Sepsis therapy 
Septic shock and sepsis involves entire team of health care, accounting for a huge 
burden on the system. Also sepsis remained a source of morbidity and mortality so 
numerous attempts were done to find a better drug, however little success have been 
achieved so far. Various immunomodulatory drugs showed good results in animal 
models. Despite promising preclinical results, the trails showed little success in 
clinical settings (Angus et al., 2001; Annane et al., 2003; Martin et al., 2003).
Clinical management usually begins with determination of the probable infection site, 
prompt recognition, early administration  directed therapy (EGDT) which involves 
crystalloid infusions, vasodilators or vasopressors, transfusion of packed red blood 
cells, and dobutamine (Balk, 2000; Balk, 2004). But this involves the whole-hearted 
involvement of the entire healthcare team which cannot be stressed enough. So the 
researchers are in search of better therapeutic agents to curb this aggressive, complex, 
and increasingly prevalent condition. Corticosteroids once seen as target drugs in 
septic shock are under controversies and are now suggested only for some patients 
sepsis whose blood pressure is poorly responsive to fluids and vasopressor therapy 
(Dellinger et al., 2008).
Another effort which created big hopes in area of sepsis therapy was development of
drotrecogin alfa (activated),which is a recombinant version of activated protein C
(APC). It was developed by Eli Lilly and Company and is marketed under the brand 
name Xigris. APC has profound anti-inflammatory properties and anti-apoptotic, 
in addition to its anticoagulant activity. The APC was seen as “magic bullet”  against 
sepsis menace, as was reported in a landmark report published in 1987 by Taylor and 
colleagues (Taylor et al., 1987), who showed that infusing protein C (derived from a 
human plasma product and activated with human thrombin) could protect baboons 
from mortality caused by injecting the animals with an otherwise lethal dose of viable 
Escherichia coli. The support to theory was given by Bernard et al. who showed in 
PROWESS study (Recombinant Human Activated Protein C (rhAPC) Worldwide 
Evaluation) that mortality of septic patients decreased when treated by rhAPC. 
However later, Eli Lilly and Company carried out a second (post marketing) clinical 
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trial of drotrecogin alfa (activated) to evaluate the efficacy of Xigris known as 
ADDRESS study (Administration of Drotrecogin alfa (activated) in Early Stage 
Severe Sepsis). The study was prematurely terminated because of the futility for 
reaching the primary study goal. The rhAPC was seen beneficial only in selective 
patients. Thus the search is still on for identifying better target and drugs for sepsis.
1.4.2 HMGB1 as therapeutic target
HMGB1-specific antibodies have been shown to protect mice against endotoxin and 
sepsis lethality. Anti-HMGB1 antibodies administered to endotoxemic animals confer 
significant protection in them from lethality (Wang et al., 1999a). Anti-HMGB1 
antibodies can be administered several hours after the early cytokine response has 
resolved, indicating that this late mediator of lethal endotoxemia can be 
therapeutically targeted through a wider window than previously described for early 
proinflammatory cytokines. These observations describe a new secondary 
inflammatory response that occurs downstream of the classical early response of 
cytokines such as IL-1 and TNF. Each of these responses can mediate lethality, but 
are distinct and can be separately inhibited to improve survival in animal models. 
TNF, the prototypical early cytokine mediator of lethal endotoxemia, causes shock, 
tissue injury and widespread necrosis in vital organs. Lethal quantities of TNF are 
produced during lethal endotoxemia and administration of similar quantities of TNF 
to normal animals causes pathological changes that are indistinguishable from over-
whelming endotoxemia, endotoxemic shock or septic shock syndrome (Tracey et al., 
1986). Inhibiting the early TNF response during endotoxemia or acute septic shock 
can prevent (Tracey et al., 1986; Tracey et al., 1987), but this scenario is dissimilar 
from the protracted time-course that characterizes systemic inflammation in humans 
without shock. HMGB1 lethality is attributable to epithelial dysfunction without the 
development of shock and tissue injury (Li et al., 2003; Sappington et al., 2002; 
Wang et al., 1999a).
Administration of anti-HMGB1 antibodies to animals with established sepsis 
significantly reverses the signs of sepsis and prevents lethality in animals with 
established infection. Three separate approaches have been reported to inhibit 
HMGB1 in rodent sepsis and each of these improves survival significantly.
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Neutralizing anti-HMGB1 antibodies have been produced and are defined based on 
their ability to inhibit the macrophage stimulating activity of recombinant HMGB1. 
Neutralizing antibodies significantly improve survival from sepsis even when the first 
dose of antibodies is administered to animals 24 h after the onset of infection (Yang et 
al., 2004). This is the widest therapeutic window described for any cytokine in this 
standardized model. Anti-TNF antibodies worsen survival from sepsis in this model 
and anti-MIF antibodies are no longer effective when administered after a 6 h window 
from the time of sepsis onset (Calandra et al., 2000; Eskandari et al., 1992).
Another strategy to inhibit the activity of HMGB1 in sepsis is to administer 
recombinant HMGB1 A box protein. Repeated administration of HMGB1 A box 
protein beginning 24h after cecal perforation significantly improves survival in 
animals with established sepsis (Yang et al., 2004). The response to A box protein is 
time and dose dependent, with maximal responses seen when A box is first 
administered either 12 or 24h after the onset of infection. Administration of A box 
36h after the onset of sepsis does not reverse mortality in this highly lethal model, 
suggesting that a clinically relevant therapeutic window for inhibiting HMGB1 may 
exist within the first 24h of the onset of sepsis.
Humanized anti-HMGB1 monoclonal antibodies could therefore find applications in 
both acute and chronic inflammatory diseases. Blockage of the RAGE signaling 
pathways could also result in attenuation of the proinflammatory effects of HMGB1. 
Several strategies, such as the administration of soluble forms of RAGE or the 
blocking of the Fab fragment derived from anti-RAGE and/or anti-HMGB1 IgG, have 
been reported (Hanford et al., 2004; Lutterloh et al., 2007). 
Considered together with the results of anti-HMGB1 antibodies and the A box 
protein, it now appears that neutralizing HMGB1 can significantly improve survival 
from established sepsis in standardized animal models. Although an antibacterial 
activity of HMGB1 has been described, inhibiting HMGB1 with either antibodies or 
A box protein did not accelerate bacterial proliferation in these models. It remains to 
be seen whether neutralizing antibodies to HMGB1 will be associated with the 
development of immunosuppression or toxicity, but results to date of treating animals 
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with either endotoxemia or sepsis have not revealed either toxicity or secondary 
infections.
Thrombomodulin has recently been shown to bind to HMGB1 so that thrombin–
thrombomodulin complexes can effectively degrade HMGB1 into a less 
proinflammatory form (Abeyama et al., 2005; Esmon, 2005; Ito et al., 2008). This 
means that recombinant thrombomodulin can promote the degradation of HMGB1 
and suppress the proinflammatory effects of HMGB1 (Ito et al., 2008). 
Thrombomodulin can also suppress coagulatory responses; therefore, recombinant 
thrombomodulin should be a promising therapeutic option against DIC or sepsis (Ito
et al., 2008).
Several small-molecule chemical compounds have been used to inhibit HMGB1 
proinflammatory activities in vivo. These pharmacological agents belong to the class 
of cytokine-release inhibitory drugs (CRIDs) and include ethyl pyruvate, the 
cholinergic agonists nicotine and acetylcholine, and steroid-like pigment tanshinone 
IIA (Chen et al., 2005; Li et al., 2007; Ulloa et al., 2002; Wang et al., 2004). These 
agents were found to interfere specifically with HMGB1 release from the nucleus into 
the extracellular space, without affecting HMGB1 mRNA or protein levels (Ulloa et 
al., 2002; Wang et al., 2004). In contrast, many other steroidal drugs and nonsteroidal 
anti-inflammatory drugs failed to significantly inhibit HMGB1 extracellular release 
(Li et al., 2007). The HMGB1 inhibiting molecules have shown impressive efficacy 
in animal models of lethal endotoxemia and sepsis, with protective effects at 
therapeutically achievable, safe doses, supporting the therapeutic potential of these 
inhibitors in HMGB1- mediated human inflammatory diseases (Chen et al., 2005; Li
et al., 2007; Ulloa et al., 2002; Wang et al., 2004). 
Ethyl pyruvate, an anti-inflammatory agent developed as an antioxidant, 
cytoprotectant in tissue ischemia, was recently discovered to be an effective inhibitor 
of HMGB1 synthesis. Administration of ethyl pyruvate to animals with established 
sepsis significantly reduced serum HMGB1 levels and significantly improved survival 
(Ulloa et al., 2002). 
Another molecule, glycyrrhizin, inhibits the chemotactic and mitogenic activities of 
HMGB1 (Mollica et al., 2007). Unlike CRIDs, glycyrrhizin does not interfere with 
Introduction, Background & Rationale
34
the release of HMGB1, but directly inhibits its extracellular cytokine activities 
(Mollica et al., 2007). This means that glycyrrhizin can inhibit not only actively 
released HMGB1 but also passively released HMGB1. However, the affinity of 
glycyrrhizin for HMGB1 is relatively modest and will need to be improved for any 
therapeutic application (Mollica et al., 2007). Several other commercially available 
drugs, such as sivelestat, nafamostat, antithrombin III, and γ-globulin, have also been 
suggested to modulate inflammatory response through HMGB1-related mechanisms 
(Hagiwara et al., 2008a; Hagiwara et al., 2007; Hagiwara et al., 2008b; Suda et al., 
2007).
1.5. Animal Models of Sepsis 
Thousands of failed preclinical trials performed over more than five decades have 
prompted a rethinking of both the pathophysiological mechanisms of sepsis and the 
use and interpretation of animal models of sepsis. On the basis of the causative agent, 
sepsis models can be divided into three categories: exogenous administration of a 
toxin (such as lipopolysaccharide (LPS), endotoxins or zymosan); exogenous 
administration of a viable pathogen (such as bacteria); or alteration of the animal’s 
endogenous protective barrier (inducing colonic permeability, allowing bacterial 
translocation). Although models have contributed significantly to our understanding 
of host defence mechanisms during infection, but there are many examples of 
controversy, when considering the application of animal models to the development 
of sepsis therapeutics. Although several models are used to study mechanisms of 
sepsis pathophysiology but the correct model to use in the development of drug 
therapy is one that most closely mimics the course of human disease. Unfortunately, 
there are significant differences between each of the current animal sepsis models that 
prevent any single one from emerging as the perfect vehicle for sepsis drug 
discovery.
Some animal models which replicate the signs and laboratory findings seen in human 
sepsis include intravascular infusion of endotoxin (Brackett et al., 1985; Johnston et 
al., 1989; Lindsey et al., 1991; Nomura et al., 1993; Pittet et al., 2000; Talke et al., 
1985; Taylor, 2001; Traber et al., 1988) or live bacteria (Di Giantomasso et al., 2003; 
Lagoa et al., 2004; Silverstein et al., 2000; Taylor, 2001), bacterial 
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peritonitis(Ahrenholz and Simmons, 1980; Fink et al., 1984; Goldfarb et al., 2002; 
Lang et al., 1983; Mathiak et al., 2000; Natanson et al., 1986; Quezado et al., 1993; 
Stamme et al., 1999), cecal ligation and perforation (Ebong et al., 1999; Richmond et 
al., 1985; Wichterman et al., 1980), soft tissue infection (Durkot and Wolfe, 1989), 
pneumonia model (Karzai et al., 2003; Murakami et al., 2002), and meningitis model 
(Ribes et al., 2003). 
1.5.1 Endotoxicosis models
Endotoxin or lipopolysaccharide (LPS), stimulates various cells to release  
inflammatory mediators which are responsible for initiating sepsis (Opal and Cohen, 
1999). LPS is a stable in its pure form and can be stored easily when in lyophilized 
form. An accurate dose can be measured according to body weight and may be 
administered as a bolus or infusion (Traber et al., 1988). In endotoxicosis,
activation of TLR4 through bolus injection of LPS leads to an overwhelming innate 
immune response, with inflammatory cytokines such as TNF representing crucial 
mediators (Murakami et al., 2002; Piper et al., 1996; Silverstein et al., 2000). This has 
formed the basis for the simplest sepsis model. Endotoxin is commonly used in 
animal models of sepsis, there are considerable differences between species in 
sensitivity to endotoxin. Humans and animals like rabbits, sheep and nonhuman 
primates are relatively more sensitive than  rodents, cats and dogs (Fink and Heard, 
1990; Michie, 1998; Piper et al., 1996).
Endotoxin, when administered to human subjects mimics many features of sepsis. In 
critically ill patients, increased concentrations of serum endotoxin have been 
associated with the development of sepsis, disease severity, and mortality (Opal and 
Cohen, 1999; Piper et al., 1996; Traber et al., 1988). The plausibility of the 
hypothesis that endotoxin plays a significant role in the pathogenesis of sepsis is 
supported by many studies that show that antibiotic administration may lead to a 
sudden release of massive amounts of endotoxin from dead bacteria and an 
acute hemodynamics worsening (Hollenberg et al., 2001; Lepper et al., 2002; Opal 
and Cohen, 1999; Piper et al., 1996; Silverstein et al., 2000).
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Inspite of various evidences (animal models) that endotoxin may play an important 
role in the pathogenesis of sepsis, several authors have expressed concerns that the 
infusion of endotoxin is not a suitable model to study sepsis.
1.5.2 Bacterial Infusion
Bacterial infection provide important insights into mechanisms of the host response 
to pathogens, however they do not recapitulate many important features of human 
sepsis. Inoculation of animals with pure or mixed bacterial flora has been a common 
tool for studying sepsis mechanisms (Deitch, 1998; Fink and Heard, 1990; 
Wichterman et al., 1980). However, high doses of bacteria commonly administered 
do not typically colonize and replicate within the host, often due to rapid lysis by 
complement (Cross et al., 1993). This leads to a potential model of intoxication with 
endotoxins rather than a true model of infection (Cross et al., 1993).
1.5.3 Cecal Ligation and Puncture (CLP) model
The CLP model is regarded as the gold standard for sepsis research (Remick et al., 
2002; Wichterman et al., 1980). The CLP model mimics the human diseases of 
ruptured appendicitis or perforated diverticulitis. The technique involves midline 
laparotomy, exteriorization of the caecum, ligation of the caecum distal to the 
ileocaecal valve and puncture of the ligated caecum. This process creates a bowel 
perforation with leakage of faecal contents into the peritoneum, which establishes an 
infection with mixed bacterial flora and provides an inflammatory source of necrotic 
tissue (Ayala et al., 2000; Wichterman et al., 1980). The severity of disease, as 
assessed by mortality, can be adjusted by increasing the needle puncture size or the 
number of punctures. The severity of CLP can be adjusted such that mortality evolves 
rapidly over hours to days, or more slowly over 28 days (Remick et al., 2005). 
A further advantage of the model is that it can identify an irreversible stage of sepsis, 
such that excision of the necrotic tissue is unable to improve survival (Latifi et al., 
2002; Remick et al., 2002). The CLP technique has achieved its popularity because of 
its general reproducibility and similarity to human disease progression. Most notably, 
the CLP model recreates the hemodynamic and metabolic phases of human sepsis 
(Wichterman et al., 1980). Subsequently, apoptosis of selected cell types and host 
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immune responses seem to mimic the course of human disease, adding further clinical 
validity to this model (Ayala and Chaudry, 1996; Hotchkiss et al., 2003). Unlike 
endotoxic shock, which produces severe hypotension and low tissue perfusion 
immediately after the administration of a large dose of endotoxin, CLP is 
characterized by a biphasic hemodynamic response, i.e., an early, hyperdynamic stage 
followed by a late hypodynamic stage of sepsis. The CLP model of sepsis, however, 
produces persistent and not episodic bacteremia, which occurs under certain clinical 
situations. The animal model of single hit sepsis utilizes healthy animals whereas in 
the clinical situation, the patient becomes septic usually following a traumatic injury 
or disease. The single hit model of sepsis may not be analogous to the patient in ICU 
with the sepsis syndrome since animals are initially healthy.
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2.1 In-Vitro study
2.1.1 Cell culture
Murine macrophage-like RAW 264.7 cells were obtained from the National 
Institute of Immunology (NII Delhi) and cultured in DMEM (Sigma Aldrich) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS, Sigma Aldrich), 
2 mM glutamine (Sigma Aldrich), and penicillin/streptomycin/gentamycin (Sigma 
Aldrich) in a humidified incubator with 5% CO2. The cells were sub-cultured in 6, 
12, 96-well plates and used at 70% confluence.
2.1.2 Peritoneal macrophage isolation and culture
The peritoneal macrophages (PMphs) were isolated from C57BL/6 by following 
procedure:
a) Mouse was euthanized and sprayed with 70% ethanol. Mouse was then 
mounted on the styrofoam block on its back.
b) Using a scissors and forceps, the outer skin of the peritoneum was cut and 
gently pulled back to expose the inner skin lining of the peritoneal cavity.
c) 5 ml of ice cold PBS (with 3% FBS) was injected into the peritoneal cavity 
using a 27G needle. The needle was inserted slowly in the peritoneum being 
careful not to puncture any organs.
d) After injection, the peritoneum was gently massaged to dislodge any attached 
cells into the PBS solution.
e) Another 25G needle attached to a 5 ml syringe was inserted in the peritoneum 
and fluid was collected while moving the tip of the needle gently to avoid 
clogging by the fat tissue or other organs. Maximum possible fluid was 
collected in tubes and the cell suspension was kept on ice.  
f) The sample having any visible blood contamination was discarded. 
g) The collected suspension was centrifuged at 2000 RPM for 5-10 min at room 
temperature.
h) The supernatant was discarded and 25 ml media (RPMI) was added. The cells 
were resuspended and centrifuged again at 1000 RPM for 20 min.
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i) The pellet was then resuspended in about <3ml media. The cells were count on 
hemocytometer after appropriate dilutions. 
j) The cells were resuspended in appropriate volume of media with RPMI + 10% 
FBS + 1x Pen/Strep + glutamine. The cells were seeded with higher density 
than normal cells in 96-well plates.
k) The cells were allowed to adhere for 3 hrs, and then washed twice (with PBS) 
to remove non-adherents cells. The cells were incubated overnight and used 
next day.
2.1.3 Compounds used and their preparation
a) Aloe-emodin preparation. Aloe-emodin (AE), purchased from Sigma-Aldrich 
(Milan, Italy), was dissolved in DMSO and stored at -20°C. Aloe-emodin was 
diluted in appropriate media immediately before use.
b) Psychosine preparation. Psychosine, purchased from Sigma-Aldrich (Milan, 
Italy), was first dissolved in DMSO and then diluted in appropriate media 
immediately before use.
c) Emodin preparation. Emodin, purchased from Sigma-Aldrich (Milan, Italy), was 
dissolved in DMSO and stored at -20°C. Emodin was diluted in appropriate media 
immediately before use.
d) Rosuvastatin preparation: Rosuvastatin, purchased locally (Novastat), was 
dissolved in PBS and stored at 4ºC. 
e) Safranal preparation: Safranal purchased from Sigma-Aldrich (Milan, Italy), was 
dissolved in methanol and stored at 4ºC.
2.1.4. Cell Viability assay
Cell viability was monitored by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) colorimetric assay. MTT is a pale yellow substrate 
that is reduced by the living cells to yield a dark blue formazan product. This 
process requires mitochondria (active) and even freshly dead cells do not reduce 
significant amounts of MTT. RAW 264.7 mouse macrophage cells were cultured
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in a 96-well flat-bottom plate for 12 h and subsequently treated with various 
concentrations of test compounds for 24 h. Thereafter, the culture medium was 
aspirated and 100 µl of MTT dye (1 mg/ml in PBS) was added into each well and 
incubated at 37ºC for 4 h. Acidified isopropanol (0.1 N HCl)was added to each
well to solubilize the blue formazan crystals. Absorbance was read at 570nm in 
microplate reader (Epoc Biotech). The index of cell viability was determined by 
measuring the OD of color produced by MTTdye reduction, compared with that of 
the untreated control cells [(OD of test compound-treated cells/OD of solvent-
treated cells) ×100].
2.1.5. Nitric oxide assay
Nitrite, a stable NO metabolite, was determined by the method of Griess Assay. 
100µl of supernatant was mixed with 100µl of Griess reagent prepared by mixing 
equal volumes of N-(1-naphthyl)ethylenediamine (NED) and sulfanilic acid and 
incubated for 15 min at room temp. The absorbance was read at 550nm in a 
microplate reader. Sodium nitrite (1.56-100uM) was used as a standard. . 
2.1.6. Western blotting analysis
Proteins were run on (8-12%) SDS-PAGE gel and transferred on PVDF
membranes using wet blotting procedure at 70V constant current. Membranes were 
washed three times with PBS for 10 minutes each and blocked for 2hr with 
ODYSSEY blocking buffer (LI-COR biotechnologies USA). Primary antibodies 
were diluted 1:1500 (anti-iNOS; sigma), 1:500 (anti-HO-1; Sigma), 1: 1000 (anti-
HMGB1; abcam, USA), 1:1000 (anti-beta tubulin; Sigma) in 0.5 % blocking 
solution and incubated overnight at 4°C on a rocking plate. Thereafter, membranes 
were washed three times with PBS-T (PBS with 0.05% Tween 20), followed by an 
incubation for 1 hr at RT with a 1:10,000 dilution of Infrared dye conjugated goat 
anti-rabbit secondary antibody (800CW) or 1:10000 dilution of Infrared dye 
conjugated goat anti-mouse secondary antibody (680CW) or 1:3000 dilution of 
Alkaline phosphate conjugated goat anti-rabbit secondary antibody. After 
subsequent washes with PBS-T, antibody binding was visualized by imaging and 
quantified on LICOR ODYSSEY infrared system or densitometry (Biorad). The 
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bands in western blots were analysed by LICOR-ODYSSEY software or Biorad 
densitometer software. 
2.1.8 HMGB1 Detection
2.1.8.1 HMGB1 precipitation and western blot
HMGB1 present in cell supernatant was precipitated by TCA/acetone method. The 
lysate was mixed with acetone and TCA(100%) in the ratio of (1:8:1) and allowed 
to precipitate at -20 °C overnight. The mixture was centrifuged at 12K rpm for 45 
min at 4 °C in a microcentrifuge. The pellet obtained was dried (but not over dried) 
and dissolved in 1× SDS-PAGE loading dye. The concentrated protein present in 
supernatant was then analysed for HMGB1 level by western blot (as above).
2.1.8.2 ELISA
An in–house ELISA was developed for detection of HMGB1 levels in small 
volumes of cell supernatant (as in peritoneal macrophages). Sandwich ELISA was 
done using two antibodies corresponding to different epitopes of HMGB1, i.e., 
anti-HMGB1 corresponding to N-terminal i.e., amino acid 2-17 (Sigma) as capture 
antibody and anti-HMGB1 corresponding to C-terminal i.e., 150 to the C-terminus 
(abcam) as detection antibody. The HRP conjugated or ALP conjugated goat anti-
rabbit secondary antibody was used for colour development with TMB or PNPP as 
substrate.
2.1.8.3 ELISPOT assay
HMGB1 was detected by in-house developed Elispot assay which allows detecting 
HMGB1 release from individual cells. 96-well plates (PVDF membrane bottomed) 
were coated with polyclonal HMGB1 antibody (specific for N-terminal, 
corresponding to amino acid 2-17 of human HMGB1; Sigma), at 4°C overnight. 
Following washing, cells were added (1000 –2000/well). The plates were
incubated in a humidified 37◦C, 5% CO2 incubator for about 3hrs and then 
stimulated as described. After appropriate time, plates were washed and second 
anti-HMGB1 antibody was added (specific for C-terminal, corresponding to amino 
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acid 150 to the C-terminus: abcam) and the plates were incubated overnight at 4°C. 
There after followed incubation with anti-rabbit alkaline phosphatase antibody 
(sigma). Colour development was via 5-bromo-4-chloro-3-indolyl phosphate p-
toluidine salt/nitroblue tetrazolium chloride chromogen liquide substrate 
(BCIP/NBT) . The reaction was stopped with water, and the plates were dried at 
room temperature overnight. Images of wells were acquired using a compound 
microscope.
2.1.9 Fluorescence Immunostaining
RAW 264.7 cells were grown to subconfluence, and stimulated with LPS in the 
absence or presence of test-compound for various period of time. Subsequently, 
cells were fixed with 2% formalin for 10 min, and permeabilized with 0.1%Triton 
X-100 in PBS (1 min, room temperature). After extensive washing with PBS, cells 
were incubated sequentially with rabbit anti-HMGB1 antibodies, and goat anti-
rabbit secondary antibodies conjugated with FITC (Santa Cruz). Nuclear 
morphology was analyzed with the fluorescent dye, Propidium Iodide. Images 
were acquired using a fluorescence microscope (Lieca).
2.2 In-Vivo study
2.2.1  Animals 
Male C57/B6 mice (15–20 wks old, 25-30g) were purchased from The Indian 
Institute of Integrated Medicine, Canal Road Jammu, India. Mice were bred and 
maintained under a 12-hr light/dark cycle at a controlled temperature (21 ± 2°C). 
Animals received pelleted rodent feed (Ashirwad Industries, Chandigarh, India) 
and water ad libitum. Animal care followed the Institutional Animal Ethics 
Committee, University of Kashmir, and the experiments were performed in
adherence to the Indian National Science Academy, New Delhi (1992) guidelines 
for the treatment of animals and ethical animal research. 
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2.2.2 Induction of Endotoxemia
To induce endotoxemia, C57BL/6 mice were injected i.p. with different amounts 
(100- 400 μg/mouse) of LPS (from Salmonella enteridis; Sigma-Aldrich) and 
observed for 24hrs for mortality and clinical signs of endotoxemia like 
piloerection, huddling, diarrhoea, weight loss  Also TNF-α levels were checked for 
analysis of development of  endotoxin induced cytokine storm. It was observed 
that lower doses (>200µg/mouse) were not able to induce high levels of TNF-α 
and/or observations associated with endotoxemia.
2.2.3 Aloe-emodin treatment protocol
Animals received 0.1ml of PBS (with 0.2% DMSO) or a similar volume of aloe-
emodin prepared in PBS (with 0.2% DMSO).  A single dose was injected 
intraperitoneally at 1hour before LPS infusion.
2.2.4 Study design
To induce endotoxemia, C57BL/6 mice were injected i.p. with sublethal (200 
μg/mouse) and lethal doses (400 μg/mouse) of LPS. Animals were treated i.p. with 
medium (controls, PBS) or with different concentrations (0.9µmol/mouse and/or 
1.3µmol/mouse as mentioned) of aloe-emodin (Sigma-Aldrich), 1hour before 
challenge with LPS. Animals were monitored after every 3 hours for survival and 
other clinical signs including piloerection, lethargy, appearance of diarrhea, and 
body weight loss. Blood samples were collected by orbital sinus for small volumes 
and cardiac puncture for terminal collection and liver, lungs, and kidney were 
collected. The blood samples were clotted for 1h at room temperature and serum 
was obtained after centrifugation for determination of cytokines. Tissue specimens 
were immediately stored in 10% formalin for histological studies or frozen in 
liquid nitrogen for protein extraction and cytokine determination, and MPO 
activity measurement. 
All animal experiments were performed under a protocol approved by the 
Institutional Animal Care and Use Committee of the University of Kashmir, 
Srinagar, J&K, India.
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2.2.5 Cytokine estimation
Supernatant of cells, mice serum and tissue homogenate was collected and frozen 
at -80ºC for cytokine analysis. Levels of various cytokines [TNF-α, IL-1β, and IL-
6] were measured using ELISA kits from eBioscience according to the 
manufacturer’s instructions.
2.2.6 Blood chemistries
Serum levels of alkaline phosphate (ALP), alanine transaminase (ALT), blood urea 
nitrogen (BUN) and creatinine were measured using an autoanalyzer (Biolyzer 
600, Blooming implex, Germany).
2.2.8 Cytokine determination
For cytokine determination in lung tissues, homogenisation of equally weighed 
tissue peices (50 mg tissue/ml) was done in phosphate buffer (50 mM, pH 7) with 
0.5%  triton, and 10 μg/ml of a cocktail of proteinase inhibitors containing phenyl
methyl sulfonyl fluoride, pepstatin, and leupeptin by Teflon homogenizer. Samples 
were centrifuged at 15,000 rpm for 45 min and stored at −80°C until cytokine 
determination. 
2.2.9 Histopathology
The lung, liver and kidney tissues were fixed in 10% formalin for about week and 
then dehydrated with different gradients of alcohol for about 3hrs. The tissues were 
then paraffin embedded and sections prepared under microtome were stained with 
hematoxylin/eosin after deparrafinization. Damage was defined on various patterns 
present in sepsis/endotoxemia. The degree of damage was estimated at 400× 
magnification using six to nine fields.
2.2.10 Myeloperoxidase assay
Neutrophil infiltration in the lung tissue was monitored by measuring MPO 
activity using 3,3’,5,5’-tetramethylbenzidine (TMB) as a reducing substrate. TMB 
reacts with peroxidase enzymes such as MPO and forms a blue product. In brief, 
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tissue specimens were homogenized at 50 mg/ml in phosphate buffer (50 mM, pH 
6.0).The homogenate was 10×diluted in acetate buffer (pH 5.4). 100µl of TMB 
reagent (2.4mM TMB, 0.3mM H2O2, 300mM NaAc (pH5.4)) was added to 100µl 
homogenate in 96-well plate. The resulting colour change was read in a microplate 
reader at a wavelength of 630 nm.
2.2.11 Statistical analysis
Values in figures and tables are expressed as mean±S.E.M of n observations, 
unless otherwise noted. All treatments were compared with relevant negative 
control (vehicle treated) and positive control (LPS treated) groups separately.  The 
statistical analysis was done by Graph pad Prism 5. The comparisons were done by 
ANOVA (in case of multiple comparisons) and t-test. The p values were derived 
by comparing separate groups individually by Beneforrini multiple comparison 
test. The survival assay was done by Gehan-Breslow-Wilcoxon Test.
2.2.11 Procurement of chemicals: 
All chemicals (unless otherwise mentioned) were purchased from Sigma Aldrich 
Germany.
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Part-I: Screening
Our strategy was to look for compounds which can inhibit HMGB1 (high mobility 
group box 1) release in activated macrophages and check effect of screened 
compound on endotoxemic mice. Anti-inflammatory molecules capable of attenuating 
HMGB1 release hold great potential in the prevention and treatment of inflammatory 
disease like sepsis/endotoxemia. So we first screened compounds on the basis of their 
nitric oxide (NO) scavenging potential in activated macrophages. NO has a 
fundamental contribution in development septic shock, its metabolites nitrite and 
nitrate rise progressively in various animal models of sepsis. The NO mediates 
hypotension leading to severe hypoxia in peripheral vital organs, resulting in 
progressive organ failure may also directly contribute to tissue and organ injury by its 
direct, peroxynitrite-mediated cytotoxic effects. 
In macrophages, LPS (lipopolysaccharide) stimulation leads to very high levels of NO 
which remain sustained to long periods because of high level expression of iNOS. NO 
has very short life span so the production of nitrite, the stable metabolite of NO was 
used as an indicator of NO production. The nitrite level can be detected in serum or 
cell culture media by Griess assay which is a simple colorimetric assay. 
3.1 Assessment of non-toxic concentration of test compounds in RAW 
264.7 cells.
Effect of different compounds on RAW 264.7 cell viability was assessed by MTT 
assay. Murine macrophage-like RAW 264.7 cells were plated in 96-well plate and 
after 12hr, various concentrations of different compounds were added. At 24hr after 
treatment, MTT assay was done. Rosuvastatin and safranal showed no significant
effect on viability, however psychosine, emodin and aloe-emodin showed decrease in 
viability at higher concentrations. The compounds were used below the 
concentrations showing any change in viability.
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Figure 3.1: Effect of different test compounds on RAW 264.7 cell viability. The 
cells were treated with test compounds (at concentrations mentioned in the figure) and 
at 24hr after treatment cell viability was determined by MTT assay, and expressed as 
the mean (±SEM) of four experiments in duplicate.
3.2 LPS induced nitric oxide (Dose and Time dependence)
LPS induced NO in RAW 264.7 cells rises to detectable range just after 6hr, but 
maximum levels are attained from 18 to 24hr. Murine macrophage-like RAW 264.7 
cells were plated in 24-well plates at 4x106 cell density. After 12hr, various 
concentrations of LPS (50ng/ml, 100ng/ml, 1µg/ml, 10µg/ml) were added. At 24hr
after LPS stimulation, supernatant was collected and nitric oxide levels were 
measured. Maximum activation was seen at 1µg/ml and 10µg/ml.  Low 
concentrations of nitric oxide were detected at 100ng/ml (Fig 3.2a). 
LPS induced nitric oxide level rise to detectable range after 6hrs, however the level 
increase with time till 24hrs. Nitric oxide was measured at different intervals of time 
after LPS stimulation.  RAW 264.7 cells plated in 24-well plate, were stimulated with 
LPS (1µg/ml) and NO levels were measured in supernatant collected at 6, 12, 18 24 
and 30hr after stimulation (Fig 3.2b).
Figure 3.2: LPS induced Nitric oxide
were stimulated with different concentrations of LPS and nitric oxide levels were 
measured in cell supernatant at 24
RAW 264.7 cells were stimulated with 1µg/ml LPS and nitric oxide levels were 
measured in cell supernatant at various time points.
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. a) Dose-dependent curve. RAW 264.7 cells 
hr after stimulation. b) Time dependent curve. 
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3.3 Effect of Rosuvastatin on LPS induced Nitric oxide levels.
The statins are a class of lipid-lowering drugs which inhibit the enzyme 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase, an early rate-limiting step in 
cholesterol biosynthesis. Statins show pleiotropic actions, affecting many pathways 
that are involved in the pathogenesis of sepsis. Various studies have been done on 
their role in sepsis and some are proving promising. Rosuvastatin a synthetic statin, is 
a competitive inhibitor of the enzyme HMG-CoA reductase, with mechanism of 
action similar to that of other statins.
To assess the role of rosuvastain in LPS stimulated inflammation in macrophages, 
RAW 264.7 cells were challenged with LPS along with rosuvastatin simultaneously. 
RAW 264.7 cells were plated and activated cells were treated with different 
concentrations of rosuvastatin (5µM 10µM and 15µM) along with LPS (1µg/ml). 
Although rosuvastatin at 5uM and 10µM concentration showed decrease in nitric 
oxide but this decrease was somehow reverted back at 15µM concentration.  Thus 
results obtained with rosuvastatin were sort of tricky to be followed.
Figure 3.3: Effect of Rosuvastatin on LPS induced nitric oxide accumulation. 
Murine macrophage-like RAW 264.7 cells were stimulated with LPS (1µg/ml) and 
different concentrations (5, 10 & 15uM0 of rosuvastatin simultaneously. Nitric oxide 
level was measured in cell supernatant at 24hr after stimulation. Data represent the 
mean ± SEM of three independent experiments (n= 3). †, p< 0.001 when compared 
with control (vehicle only).
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3.4 Effect of Safranal on LPS-induced Nitric oxide levels.
Safranal is an organic compound isolated from Crocus sativus L. (Iridaceae). Studies 
have showed high antioxidant and free radical scavenging activity of safarnal.  Also 
because of anti-inflammatory actions of crocus extracts, it seems interesting to study 
its effect on LPS induced oxidative stress in RAW 264.7 cells.
To determine the effect of safranal on nitric oxide release by macrophages, murine 
macrophage line RAW 264.7 cells were stimulated with LPS in the presence of
safranal and nitric oxide levels checked. RAW 264.7 cells were plated and then 
treated with safranal (20, 30, 40µM) in combination with LPS (1µg/ml), 24hr later the 
supernatant was collected and nitric oxide levels measured by Griess assay. The 
safranal seemed to change the nitric oxide levels (as per Griess assay), however there 
was a slight decrease in nitric oxide level even in drug control, additionally the colour 
of medium changed significantly, interfering the assay. 
In order to check the actual effect of safranal on NO, the expression of iNOS (which 
is responsible for high level of NO release in macrophages) was checked, The effect 
on iNOS protein expression was studied by immunoblot, equal amounts of protein 
(50µg) were resolved in SDS-PAGE and then transferred to a PVDF membrane and 
the expression of iNOS was then detected using specific antibodies. The detection of 
β-actin was also performed as an internal control. The intensity of protein bands were 
analyzed using blot analysis software, which showed no change in iNOS levels by 
safranal treatment thereby providing supporting evidence that safranal  has
insignificant effect on LPS induced nitric oxide levels.
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Figure 3.4: Effect of Safranal on LPS induced nitric oxide and iNOS. Murine 
macrophage-like RAW 264.7 cells were stimulated with LPS (1µg/ml) and 
different concentrations of safranal; a) At 24hr after stimulation, nitric oxide level 
was measured in supernatant by Griess assay; b) At 24hr after stimulation, iNOS 
levels in RAW 264.7 cells. Data represent the mean ± SEM of three independent 
experiments (n = 3). †, p< 0.001 when compared with control (vehicle only).
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3.5 Effect of psychosine on nitric oxide levels
Psychosine is the trivial name for a monoglycosylsphingolipid, which is the lyso or 
non-acylated form of a cerebroside, e.g. galactosylsphingosine. To analyse anti-
inflammatory potential of psychosine in RAW 264.7 macrophage cells, cells were 
treated with two different concentrations of psychosine (4 & 8µM) simultaneously 
with LPS (1µg/ml). After 24hr the supernatant was collected. The effects of 
psychosine on LPS-induced nitric oxide levels in supernatant were examined at 24hr 
after stimulation. Psychosine at lower concentration (4µM) induced comparatively 
less reduction in the levels of nitric oxide level, however there was a significant 
(p<0.05) decrease in nitric oxide levels at higher concentration of psychosine (8µM).
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Figure 3.5: Effect of psychosine on LPS induced nitric oxide. Murine macrophage-
like RAW 264.7 cells were stimulated with LPS (1µg/ml) and different concentrations 
of psychosine (4 and 8µM).  At 24hr after stimulation, nitric oxide level was 
measured in supernatant by Griess assay. Data represent the mean ± SEM of three 
independent experiments (n = 3).†, p< 0.001 when compared with control (vehicle 
only) **p < 0.05 when compared with the group treated with LPS (1 µg/ml) alone ; p-
values were calculated by Bonferroni non-parametric ANOVA test. 
Results
53
3.6 Effect of emodin on nitric oxide levels in RAW 264.7 cells
Emodin is seen in various plants of medicinal importance. In order to investigate the 
effect of emodin on LPS-induced nitric oxide levels in cell supernatant, RAW 264.7 
macrophage cells were stimulated with LPS (1 µg/ml)  along with two concentrations 
of emodin (6 & 12µM). 24hr later cell supernatant was obtained for nitric oxide 
measurement. The emodin showed significant inhibitory effect on nitric oxide levels 
at both 6 and 12µM concentrations.
By the time of our experiments, some researchers showed that emodin inhibited 
HMGB1 release in activated RAW 264.7 cells (Chen et al 2010).
Figure 3.6: Effect of emodin on LPS induced nitric oxide. Murine macrophage-like 
RAW 264.7 cells were stimulated with LPS (1µg/ml) and different concentrations of 
emodin.  At 24hr after stimulation, nitric oxide level was measured in supernatant by 
Griess assay. Data represent the mean ± SEM of three independent experiments (n = 
3). †,p< 0.001 when compared with control (vehicle only), **p < 0.01  and 
***p<0.005 when compared with the group treated with LPS only; p-values were 
calculated by Bonferroni non-parametric ANOVA test. 
3.7 Effect of aloe-emodin on nitric oxide in RAW 264.7 macrophages
Recent research has shown beneficial effects of aloe
however not much is known about its eff
of aleo emodin (AE) on nitric oxide production, 
treated with AE (5, 10 & 15µM) along with LPS (1µg/ml).
induction, NO concentrations were measured in the cult
assaay. Aloe-emodin significantly inhibited LPS
dependent manner with 15µM inhibiting the most.
Figure 3.7: Effect of aloe
macrophage-like RAW 264.7 cells were treated with different concentrations of AE 
and LPS (1µg/ml).  At 24
supernatant by Griess assay. Data represent the mean ± SEM of three independent 
experiments (n = 3) done in duplicate. †,p<0.001 when compared with control 
(vehicle only), **p < 0.01  and ***p<0.005 when compared with the group treated 
with LPS only; p-values were calculated by Bonferroni non
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Part II- Psychosine
3.8 Effect of psychosine on Nitric oxide release
Psychosine is the trivial name for a monoglycosylsphingolipid, which is the lyso or 
non-acylated form of a cerebroside, e.g. β-galactosylsphingosine. It is a minor 
intermediate in the catabolism of monoglycosylceramides, and is normally present in 
brain tissues at very low concentrations. In Krabbe disease, deficiency of galactosyl 
ceramidase results in accumulation of psychosine. Psychosine mediates apoptosis in 
oligodendrocytes and the debris activates microglial cells (resident macrophages in 
the brain), which are the primary mediators of neuroinflammation. However the effect 
of psychosine on peripheral cells is still unknown.
We examine the possibility of NO scavenging property in LPS stimulated murine 
macrophage-like RAW 264.7 cells.
RAW 264.7 macrophage cells were treated with LPS in the presence of two different 
concentrations of psychosine (4µM and 8µM) and nitric oxide level in cell 
supernatant was examined after 24hr. Psychosine treatment showed a concentration
dependent effect with lower concentration (4µM) inducing decrease in the levels of 
nitric oxide level and a significant (p<0.05) decrease in nitric oxide levels at higher 
concentrations (8µM) (Fig 3.8a). 
It was recently observed that psychosine effect varies from individual cell lines to that 
of mixed primary cell cultures. So assessing the psychosine effects in primary murine 
peritoneal macrophages (primary cell culture) was essential. Primary murine 
peritoneal macrophages (PMphs) were isolated from C57BL/6 and incubated 
overnight in RPMI.  PMphs were then stimulated with LPS (1µg/ml) along with 
different concentrations of psychosine. At 24hr, after stimulation NO levels were 
checked in cell supernatant by Griess assay. In PMphs, LPS induced  significant 
increase in nitric oxide in comparison to control however the psychosine treatment in 
stimulated cells slightly increased the nitric oxide levels although not significant 
enough (p>0.05). The treatment of psychosine alone also showed slight increase in 
nitric oxide levels.
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Figure 3.8. Effect of psychosine on LPS-induced nitric oxide release a) RAW 264.7 cells 
b) Primary murine peritoneal macrophages. The nitric oxide levels in supernatant were 
checked at 24hr after LPS stimulation in the presence of pychosine. Data from at least three 
experiments were normalized by denoting the NO levels in supernatant of LPS stimulated
cells as 100% and subsequently calculating the effect achieved by addition of psychosine.  
Data represent the mean ± SEM of three independent experiments (N = 3). †p< 0.001 when 
compared with control (vehicle only), *p < 0.05 and **p < 0.01when compared with the 
group treated with LPS (1 µg/ml) alone ; p-values were calculated by Bonferroni non-
parametric ANOVA test.
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3.9 Effect of psychosine on LPS induced HMGB1 release
Psychosine showed different effect on LPS induced nitric oxide in RAW cells and 
primary PMphs. Since our main target was HMGB1, so we went ahead to check the 
effect of psychosine on LPS induced HMGB1 release. HMGB1 which is released 
actively by LPS or TNF-α stimulated macrophages, is released quite late than early 
mediators (TNF, IL-1), it is thus known as later mediator of sepsis and is detectable 
after 18hr.
To study the effect of psychosine on LPS-induced HMGB1 release, cells were treated 
with different concentrations of psychosine (4µM & 8µM) and HMGB1 release was 
checked by immunoblot. RAW 264.7 macrophage cells were pretreated with 
psychosine and then stimulated with LPS (1µg/ml). After 24hr of stimulation, 
supernatant was collected and total protein concentrated by precipitation was resolved 
in SDS-PAGE gel and then transferred to a PVDF membrane. The blot was first 
stained with ponceau S for checking equal protein load and then using specific 
antibody for HMGB1, expression was analysed. It was seen that, psychosine at both 
concentrations had no significant effect on the LPS-induced release of HMGB1 (Fig
3.9a). 
Since psychosine showed different effects on NO levels in RAW 264.7 cells and 
primary PMphs, so we analysed if psychosine has any effect on HMGB1 release in 
different cellular environment. PMphs were isolated from C57BL/6 and incubated 
overnight in RPMI. PMphs were then incubated with psychosine (4 & 8µM) and 
stimulated with LPS (1µg/ml). Supernatant was collected at 24hr after LPS 
stimulation, and HMGB1 levels were checked by in-house ELISA. In combination 
with LPS, psychosine increased the release of HMGB1, with higher concentration 
(8µM) increasing most, psychosine alone also showed small but significant increase 
in HMGB1 levels.
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Figure 3.9: Effect of psychosine on LPS induced HMGB1 release a) The HMGB1 
expression in RAW 264.7 cell supernatant was seen by western blot at 24hr after LPS 
stimulation. Density of the protein bands were expressed (in arbitrary units (AU)) as mean
± SEM of 2 independent experiments (Ponceau S staining was done for checking equal load 
of protein) b) HMGB1 release in PMphs cell supernatants was detected by in-house ELISA. 
Data from at least three experiments were normalized by denoting the HMGB1 release from 
LPS stimulated cells as 100% and subsequently calculating the effect achieved by addition of 
psychosine.  The values are expressed in mean (±SEM) of two experiments in duplicate. †p< 
0.05 and †††p< 0.001 when compared with control and ***p<0.001 when compared with 
LPS group; p-values were calculated by Bonferroni non-parametric ANOVA test.
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3.10 Effect of psychosine on LPS induced TNF-α
Psychosine increased HMGB1 release in primary PMphs without effecting its release 
in RAW 264.7 cell levels. As HMGB1 release is dependent partly on TNF-α 
stimulation so it was interesting to check the effect of psychosine on TNF-α levels in 
two cellular milieu. Murine macrophage-like RAW 264.7 cells were stimulated with 
LPS and treated with different concentrations of psychosine. At 12hr after 
stimulation, TNF-α level was measured in cell supernatant by ELISA. It was observed 
that psychosine at high concentrations (8µM) attenuated the rise in levels of TNF-α 
significantly compared to LPS stimulated group. At lower concentrations (4µM) 
psychosine decreased the TNF-α level but the decrease was not significant enough.
Parallel experiments as above were done in PMphs, which were stimulated with LPS 
(1µg/ml) along with different concentrations of psychosine. The TNF-α levels were 
measured in cell supernatant at 12hr after stimulation. Psychosine in contrast to RAW 
264.7 cells increased the TNF-α level in combination with LPS. Psychosine alone 
slightly increased the TNF-α level compared to control (not significant, p>0.05), 
however when PMphs were treated in combination with psychosine the TNF-α levels 
were raised in concentration-dependent manner with higher concentration (8µM) 
showing significant increase than lower concentrations.
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Figure 3.10: Effect of psychosine on LPS induced TNF-α levels. a) RAW 264.7 b) 
PMphs. The TNF-α levels were checked at 12hr after LPS stimulation in the presence 
of psychosine using ELISA. Data from at least three experiments were normalized by 
denoting the TNF-α release from LPS stimulated cells as 100% and subsequently calculating 
the effect achieved by addition of psychosine. The values are expressed in mean (±SEM) 
of three experiments in duplicate. †p< 0.001 when compared with control; **p < 0.01
and ***p<0.001 when compared with the group treated with LPS (1 µg/ml) alone; p-
values were calculated by Bonferroni non-parametric ANOVA test.
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Part III- Aleo-Emodin
(In-vitro study)
Aloe emodin is present in various plants of medicinal importance. It belongs to a 
family of compounds called anthraquinones, which are reported to possess anti-
inflammatory and anticancer effects. As reported in screening aloe-emodin showed a 
significant decrease in LPS-induced nitric oxide level, so we now had to optimise the 
timing of aloe-emodin(AE)  treatment relative to LPS treatment on the basis of NO 
levels.
3.11 Effect of Aloe-emodin on LPS induced NO (optimisation of 
timing)
LPS was used to stimulate NO production in RAW 264.7 mouse macrophage cells. 
The cells were treated with aloe-emodin (5, 10 & 15µM) but at different time points 
relative to LPS treatment i.e., pre-treatment (1h before LPS treatment), simultaneous 
(along with LPS), post-treatment (1h after LPS treatment). After 24hr, nitrite 
concentration (µM) was determined in cell supernatants. The nitrite production in
RAW 264.7 mouse macrophages was inhibited significantly at 10µM and 15µM 
concentrations of AE, however pre-treatment with LPS further increased its 
significance and consistency (Fig 3.11). Keeping in view the results, aloe-emodin
treatment was done 1hr before LPS stimulation in all experiments.
The NO scavenging potential of aloe-emodin was also checked in LPS induced 
primary murine peritoneal macrophages (PMphs). PMphs, isolated from C57BL/6, 
plated at equal density in 96-well plate and incubated overnight in RPMI. PMphs 
were pretreated with different concentrations of aloe-emodin (5, 10 & 15µM) for 1hr 
and then stimulated with LPS (1µg/ml). 24h after LPS stimulation, NO was estimated 
in supernatant by Griess assay. It was observed that aloe-emodin at 10 µM and 15µM 
concentration decreased LPS induced NO levels in concentration dependent manner.
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Figure 3.11: Effect of aloe-emodin treatment (timing) on LPS-induced nitric 
oxide release. RAW 264.7 cells were treated with aloe-emodin at different timings 
relative to LPS treatment i.e., a) pre-treatment for 1hr b) simultaneous treatment c) 
post- treatment for 1h d) PMphs isolated from C57BL/6 and treated with aloe-emodin 
(pre-treated for 1hr) and LPS (1µg/ml). NO levels checked 24h after LPS treatment. 
Data from at least three experiments were normalized by denoting the NO levels in 
supernatant of LPS stimulated cells as 100% and subsequently calculating the effect 
achieved by addition of aloe-emodin.  Data represent the mean ± SEM of three 
independent experiments (N = 3). †p< 0.001 when compared with control (vehicle), 
*p < 0.05, **p < 0.01 and ***p < 0.001when compared with the group treated with 
LPS (1 µg/ml) alone ; p-values were calculated using Bonferroni non-parametric 
ANOVA test.  
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3.12 Effect of Aloe-emodin on iNOS expression 
In order to investigate whether the aloe-emodin mediate inhibition of NO production 
was due to a decreased protein expression of iNOS, the effect on iNOS protein 
expression was studied by immunoblot. Equal amounts of protein (50µg) were 
resolved in SDS-PAGE and then transferred to a PVDF membrane and the expression 
of iNOS was then detected using specific antibodies. The results showed that 
incubation with aloe-emodin (15 µM) after 24 h inhibited iNOS protein expression in 
RAW 264.7 mouse macrophage cells. The detection of β-actin was also performed as 
an internal control. The intensity of protein bands were analyzed using blot analysis 
software, showing an average of 60% down-regulation of iNOS protein after 
treatment with aloe-emodin (15µM) compared to positive control (LPS) (Fig 3.12).
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Figure 3.12: Effect of aloe-emodin on LPS-induced iNOS. RAW 264.7 cells were 
treated with 1 µg/mL of LPS alone (positive control) or with aloe-emodin (15 µM) for 
24 h. The iNOS expression was analysed by western blot with β-actin as loading control and 
density of the protein bands were expressed (in arbitrary units (AU)) as mean ± SEM of 2 
independent experiments. The values are expressed in mean (±SEM) of two experiments in 
duplicate. †p< 0.001 when compared with control and ***p<0.001 when compared with LPS 
group; p-values were calculated by Bonferroni non-parametric ANOVA test.
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3.13 Effect of Aloe-emodin on LPS induced HMGB1 release
In response to stimulation with lipopolysaccharide (LPS) or endogenous 
proinflammatory cytokines [such as tumour necrosis factor (TNF), interleukin (IL)-
1β, interferon (IFN)-γ], cultures of macrophages/monocytes actively release HMGB1. 
HMGB1 is time-dependently released from endotoxin-stimulated macrophage 
cultures, with significant HMGB1 accumulation first detectable at 8hr after 
stimulation. 
To study the effect of aloe-emodin (AE) on LPS-induced HMGB1 release, stimulated 
cells were treated with different concentrations of aloe-emodin (5µM, 10µM, 15µM) 
and HMGB1 release was checked by immunoblot. RAW 264.7 macrophage cells 
were pretreated with aloe-emodin for 1hr and then stimulated with LPS (1µg/ml). 
After 24hr of stimulation, supernatant was collected and total protein concentrated by 
precipitation was resolved in SDS-PAGE gel and then transferred to a PVDF 
membrane. The blot was first stained with Ponceau S for checking equal protein load 
and then HMGB1 expression was done using specific antibody for it, expression was 
analysed. It was observed that aloe-emodin inhibited the LPS induced release in 
concentration-dependent manner, with 15µM inhibiting the release most (Fig 3.13a).
The HMGB1 inhibiting potential of aloe-emodin was also checked by in-house 
developed ELISPOT assay. Around 2000 cells were added per well (96-well coated 
with PVDF membrane) and after overnight incubation the cells were treated with 
aloe-emodin (15µM) for 1 h and then stimulated with LPS (1µg/ml). After 24h the 
plate was processed and HMGB1 release was detected by spots on membrane. Spots 
indicates the HMGB1 release and comparing spots it was seen that aloe-emodin 
treatment significantly reduced the LPS induced release in RAW 264.7 cells (Fig
3.13b).
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Figure 3.13: Effect of aloe-emodin on LPS-induced HMGB1 release. RAW 264.7 
cells were pre-treated with aloe-emodin for 1hr before stimulation with LPS (1µg/ml). a) The 
HMGB1 expression in culture medium was seen by western blot at 24hr after LPS 
stimulation. The blot was stained with Ponceau S for checking equal loading and density of 
the protein bands were expressed (in arbitrary units (AU)) as mean ± SEM of 2 independent 
experiments b) Secretion of HMGB1 was also detected by ELISPOT. Data from at least three 
experiments were normalized by denoting the number of spots from LPS stimulated cells as 
100% and subsequently calculating the effect achieved by addition of the drug.
We further confirmed 
murine peritoneal macrophages (PMphs). PMphs were isolated from C57BL/6 and 
incubated overnight in RPMI. PMphs were then pretreated with different 
concentrations of AE (5, 10 & 15µM) for 1hr and st
Supernatant was collected 24
checked by in-house ELISA. The results were interpreted in comparison to positive 
control (LPS). It was seen that HMGB1 release is decreased in primary PMphs in 
concentration-dependent manner with 15
(Fig 3.14).
Figure 3.14: Effect of aloe
peritoneal macrophages
pretreatment with different doses of aloe
was detected by in-house ELISA. 
denoting the HMGB1
calculating the effect achieved by addition of aloe
(±SEM) of three experiments in duplicate.
**p<0.01 and ***p<0.001 when compared with LPS group; p
Bonferroni non-parametric ANOVA test.
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3.14 Effect of Aloe-emodin on HMGB1 translocation
HMGB1 release by activated macrophages is not due to cell death, but dependent on 
active translocation of HMGB1 from the nucleus to the cytoplasm and then to extra-
cellular space. HMGB1, which is predominantly localized in the nucleus of 
macrophages, is released to the extracellular space by macrophages on stimulation 
with LPS.  As aloe-emodin was seen to inhibit the HMGB1 release outside cell so we 
next checked if aloe-emodin treatment effected the nuclear cytoplasmic distribution in 
activated macrophages.
The LPS induced translocation from nucleus to cytoplasm in LPS-stimulated RAW 
264.7 cells was checked by immunofluorescence. It was seen after 16h, HMGB1 
which is localized predominantly in nucleus in control cells, is significantly 
translocated to cytoplasm by LPS treatment. However aloe-emodin treatment 
markedly inhibited LPS-induced HMGB1 cytoplasmic translocation and preserved its 
nuclear localization (Fig 3.15).  
HMGB1 is constitutively expressed in normal and stimulated cells and stimulation 
with LPS or TNF, induces the nuclear HMGB1 translocation to cytoplasm without 
effecting the gene expression. To check effect of aloe-emodin or LPS or both on 
HMGB1 expression, total levels of HMGB1 was checked in macrophages. RAW 
264.7 cells were treated with aloe-emodin for 1hr and at 16hr after LPS stimulation, 
cells were lysed. Equal amounts of protein (100µg) were resolved in SDS-PAGE and 
then transferred to a PVDF membrane. The expression of HMGB1 and β-actin 
(loading control) was then detected using specific antibodies (Fig 3.16a). To check 
HMGB1 release by LPS (alone or in comibation with aloe-emodin) in stimulated 
RAW 264.7 cells is not due to cell death we observed the effect of LPS 
alone/combination on cell viability (Fig 3.16).
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Figure 3.15: Effect of aloe-emodin on LPS-induced HMGB1 translocation. RAW 
264.7 cells were cultured for 24 hours without exogenous stimulus (Normal), or with 
LPS (1µg/ml) or with LPS+AE (15µM). The cells were then fixed and stained by 
immunofluorescence to identify HMGB1 (green) or cell nuclei (red, Propidium 
Iodide). HMGB1 was dominantly expressed intranuclearly in unstimulated cells, Cells 
activated with LPS demonstrated HMGB1 presence both in the nucleus and 
cytoplasm compared to cells in control. Cells activated by LPS in the presence of AE 
(15µM) expressed the strong nuclear intensity compared to LPS treated cells.
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Figure 3.16: Effect of aloe-emodin on HMGB1 expression and cell viability. 
RAW cells were stimulated with AE (15µM) and LPS (1µg/ml) a) After 16hr, western 
blot of total cell lysate was done using β-actin as loading control. Density of the 
protein bands were analyzed and expressed (in arbitrary units (AU)) as mean ± SEM of 2 
independent experiments. b) Cell viability assay (MTT assay) was done after 24hr. Data from 
at least three experiments were normalized by denoting the cell viability from 
unstimulated/untreated cells as 100% and subsequently calculating the effect achieved by 
addition of AE (15µM) and or LPS (1µg/ml).  The values are expressed in mean (±SEM) of 
three experiments in duplicate.
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3.15 Effect of Aloe-emodin on pro-inflammatory cytokines in 
activated macrophages.
LPS induced macrophages/monocytes to sequentially release early (TNF-α and IL-1β) 
and late (HMGB1) proinflammatory cytokines. Early cytokines are released initially 
to protect from damage but high levels result in dysregulated inflammation and tissue 
injury. Aloe-emodin decreased the release of late mediator HMGB1, so we now 
analysed its effect on early mediators.
TNF-α
TNF-α is regarded as a pro-inflammatory cytokine that is produced in response to 
injury, exerting a large number of important roles in the immune system and during 
inflammatory responses. In response to LPS, macrophages releases TNF-α in few 
hours which then enhance the LPS action by inducing release of other pro-
inflammatory cytokines.
To determine the effect of aloe-emodin on LPS induced pro-inflammatory cytokine 
release, experiments on RAW 264.7 cells and primary PMphs were done. 
RAW 264.7 macrophage cells pre-treated with AE for 1hr with three different 
concentrations, were stimulated with LPS. After 12h of stimulation, the TNF-α levels 
were measured in cell supernatant by ELISA. It was seen that LPS stimulation 
increased the TNF-α levels from 41.75±2.32 pg/ml (control) to 233.9± 17.02 pg/ml in 
12 h. The AE treatment decreased the TNF-α levels in concentration-dependent 
manner, with 5µM (202.6±8.727 pg/ml) showing no significant change in levels, 
however higher concentrations decreasing TNF-α significantly (10µM concentration, 
159.3±13.27 pg/ml: 15µM concentration, 84.64±6.91 pg/ml) (Fig 3.17a). 
We further confirmed the effect of AE on TNF-α using primary murine peritoneal 
macrophages (PMphs). PMphs were isolated from C57BL/6 mice and incubated 
overnight in RPMI. PMphs were then pretreated with different concentrations of aloe-
emodin (5, 10 & 15µM) for 1hr and stimulated with LPS (1µg/ml). Supernatant was 
collected at 12 h after LPS stimulation, and TNF-α levels were checked by ELISA. It 
was observed that TNF-α levels increased significantly after LPS treatment and aloe-
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emodin inhibited LPS induced increase in TNF-α levels significantly (p<0.001) in 
concentration-dependent manner (Fig 3.17b).
Figure 3.17: Effect of aloe-emodin on TNF-α release in activated macrophages a)
RAW 264.7 cells b) PMphs, isolated from C57BL/6 mice. Cells were treated with 
AE for 1hr and followed by stimulation with LPS (1µg/ml). The TNF–α levels were 
checked at 12hr after LPS stimulation. Data from at least three experiments were 
normalized by denoting the TNF-α release from LPS stimulated cells as 100% and 
subsequently calculating the effect achieved by addition of aloe-emodin. The values 
are expressed in mean (±SEM) of three experiments in duplicate. †p< 0.001 when 
compared with control; **p < 0.01 and ***p<0.001 when compared with the group 
treated with LPS (1 µg/ml) alone; p-values were calculated by Bonferroni non-
parametric ANOVA test.
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IL-1β
IL-1 is synthesized by mononuclear phagocytes, polymorphonuclear leucocytes and 
other cell types and affects a wide variety of tissues. IL-1β is the predominant form of 
this mediator produced by endotoxin-stimulated human monocytes and detected in the 
plasma of septic animals. 
To determine the effect of aloe-emodin on LPS induced IL-1β release, experiments on 
RAW 264.7 cells and primary PMphs were done. 
RAW 264.7 macrophage cells pre-treated with aloe-emodin, for 1hr with three 
different concentrations, were stimulated with LPS. After 12h of stimulation, the IL-
1β levels were measured in supernatant by ELISA. It was seen that LPS stimulation 
increased the IL-1β levels from 10.55±1.381 pg/ml (control) to 66.56±11.35 pg/ml in 
12 h. The aloe-emodin treatment decreased the IL-1β levels in concentration-
dependent manner, with 5µM (51.20±3.975 pg/ml) showing no significant change in 
levels, however higher concentrations decreasing IL-1β significantly (10µM
concentration, 36.32±3.777 pg/ml: 15µM concentration, 39.24±1.505 pg/ml) (Fig 
3.18a). 
We further confirmed the effect of aloe-emodin on IL-1β release in LPS stimulated 
primary murine peritoneal macrophages (PMphs). PMphs were isolated from 
C57BL/6 and incubated overnight in RPMI. PMphs were then pretreated with 
different concentrations of aloe-emodin (5, 10 & 15µM) for 1hr and stimulated with 
LPS (1µg/ml). Supernatant was collected at 12hr after LPS stimulation, and IL-1β 
levels were checked by ELISA. It was observed that IL-1β levels increased 
significantly after LPS treatment and aloe-emodin inhibited the increase in IL-1β 
levels significantly (p<0.001) in concentration-dependent manner (Fig 3.17b).
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Figure 3.18: Effect of aloe-emodin on IL-1β release in activated macrophages a)
RAW 264.7 cells. b) PMphs cells isolated from C57BL/6. The IL-1β levels were 
checked at 12hr after LPS stimulation. Data from at least three experiments were 
normalized by denoting the IL-1β release from LPS stimulated cells as 100% and 
subsequently calculating the effect achieved by addition of aloe-emodin. The values are 
expressed in mean (±SEM) of three experiments in duplicate. †p< 0.001 when 
compared with control; **p < 0.01 and ***p<0.001 when compared with the group 
treated with LPS (1 µg/ml) alone; p-values were calculated by Bonferroni non-
parametric ANOVA test.
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3.16 Effect of Aloe-emodin on Heme-oxygenase 1 expression
Heme-oxygenase (HO-1) catalyzes the conversion of heme into free iron, carbon 
monoxide (CO) and bilirubin (a metabolite of biliverdin), which mediate its actions. 
The HO-1 system exerts anti-oxidant, anti-apoptotic, and immunomodulatory 
functions in various situations and the productions of HO-1 ameliorate the injury in 
endotoxin-induced organ dysfunction in animal models. Up-regulation of HO-1 is 
seen to protect mice from the lethal effect of LPS- and CLP-induced sepsis, paralleled 
by a decrease in the systemic levels of HMGB1.
RAW 264.7 cells were pre-treated with aloe-emodin for 1h and then stimulated with 
LPS. At 12 h after LPS stimulation, HO-1 expression was analysed by western blot. 
Equal amounts of protein were resolved in SDS-PAGE gel and transferred to PVDF 
membrane. The expression of HO-1 and β-actin (loading control) was then detected 
using specific antibodies. The blot showed HO-1 induction with LPS and aloe-emodin 
treatment increased the HO-1 expression in stimulated macrophages, expression was 
also seen in cells treated with aloe-emodin only (Fig 3.19).
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Figure 3.19: Effect of aloe-emodin on HO-1 induction. RAW 264.7 cells were 
treated with 1 µg/mL of LPS alone (positive control) and or with aloe-emodin (15 
µM) for 12 h. The HO-1 expression was analysed by western blot with β-actin as loading 
control and density of the protein bands was expressed (in arbitrary units (AU)) as mean ±
SEM of 2 independent experiments. The values are expressed in mean (±SEM) of two 
experiments in duplicate. †p< 0.001 when compared with control and **p<0.01 when 
compared with LPS group; p-values were calculated by Bonferroni non-parametric ANOVA 
test.
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PART III- ALEO-EMODIN
(In-vivo study)
Endotoxin or LPS is the principal component of the gram-negative bacterial cell wall, 
stimulates the release of various pro-inflammatory mediators from various cell types, 
responsible for initiating the process of septic shock or sepsis. LPS is a stable, 
relatively pure compound that can be stored in lyophilized form. Bolus administration 
or infusion results in simplest sepsis model commonly called as endotoxemia. 
Endotoxin is commonly used in animal models of sepsis, as it is simplest and mimics 
most of features, predominantly early features of sepsis. 
3.17 Standardization of mice model of endotoxemia
Infusion of bolus injection of LPS (i.p., or i.v.) results in sepsis like condition known 
as endotoxemia. Although various studies have standardised the optimum dose of LPS 
for onset of endotoxemia in C57BL/6 mice, however the dose varies as per the 
conditions. Mice were randomly grouped and were injected with different doses of 
LPS (i.p.). The onset of endotoxemia was confirmed by the levels of TNF-α in early 
stages i.e., at 3-4h after LPS administration. After testing various doses, two doses
were selected, sublethal i.e. 200µg/mouse and lethal i.e. 400µg/mouse.
3.18 Effect of Aloe-emodin pretreatment in mice model of 
endotoxemia
Mice were pretreated with two doses of aloe-emodin (AE) (0.9µmol/mouse and 
1.3µmol/mouse, i.p) for 1hr and then sub lethal dose of LPS (200µg/mouse) was 
administered (i.p.). The survival of animal was monitored for 60hr. It was seen, aloe-
emodin at 0.9µmol/mouse increased the survival rate significantly than at higher dose 
(1.3µmol/mouse) (p<0.05) (Fig 3.21a). We then explored efficacy of aloe-emodin 
(0.9µmol/mouse) in animal model of lethal endotoxemia induced by intra peritoneal 
administration of higher dose of LPS (400µg/mouse). Aloe-emodin (0.9µmole/mouse) 
pretreatment for 1hr showed survival rate of 71% compared to 0% in LPS treated 
group (Fig 3.21b). Aloe-emodin pretreatment also attenuated the clinical 
manifestations of endotoxemia including huddling, lethargy, diarrhea, piloerection, 
and malaise developed within few hours after induction.
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Figure 3.20: Effect of aloe-emodin on survival of endotoxemic mice. a) C57BL/6 
mice were injected intra peritoneally with 0.9µmol and 1.3µmol/mouse for 1hr before 
LPS (200µg/mouse) injection. The mortality rate was monitored for 60hr. b) In 
similar experiment, mice were pretreated with aloe emodin (0.9µmol/mouse)  for 1h 
and then injected with LPS (400µg/mouse). Survival was monitored for 60hr. n = 10–
12 mice/group. ***,p<0.001,  *,p < 0.005 versus control mice, survival analysis done 
by Gehan-Breslow-Wilcoxon Test.
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3.19 Effect of Aloe-emodin on cytokine levels in endotoxemic mice
Cytokines are main mediators of pathology of sepsis/endotoxemia as they are elevated 
within hours of onset of disease. Administration of recombinant TNF-α or IL-1β to 
animals mimics the features of septic shock, and treatment with anti TNF-α antibodies 
or blocking the effects of IL-1 with IL-1receptor antagonist (IL-1Ra) protect animals 
from lethal endotoxemia and gram-negative sepsis. TNF-α and IL-1β concentrations 
have been widely evaluated in septic patients, and found to be increased, correlating 
with the severity of sepsis. From survival analysis curve, it was seen that aloe-emodin
showed better survival rates at 0.9µmol/mouse than at 1.3µmol/mouse. 
TNF-α
TNF-α is a primary mediator of inflammation, and has been implicated in a large 
number of infectious and non-infectious inflammatory diseases. Elevated levels of 
TNF-α are seen in both septic patients and animal models of sepsis. Also antibodies 
targeting TNF-α have been observed to have beneficial effects in septic shock. 
We checked the effect of aloe-emodin (AE) on TNF-α at two doses of LPS (sub lethal 
and lethal dose of LPS). It was seen that of aloe-emodin pretreatment, decreased the 
elevation levels of TNF-α in endotoxemic mice. In control group, the levels ranged 
between 6.46±1.847 pg/ml in both the groups. The serum TNF-α level increased
within an hour after LPS administration and after 4hr it was seen that TNF-α level 
reached upto 1097±98.46 pg/ml (LPS- 400µg/mouse) and 481.1±9.468 pg/ml (LPS-
200µg/mouse). Pre-treatment of aloe-emodin for 1hr induced marked suppression in 
the increase of serum level of TNF-α at 4hr after LPS stimulation. In low dose LPS 
model, two doses of aloe-emodin were used (0.9µmol/mouse and 1.3µmol/mouse), 
both decreasing the TNF-α levels in serum significantly with 1.3µmol/mouse 
(162.1±3.704 pg/ml) decreasing more than 0.9µmol/mouse (280.5±27.19 pg/ml). In 
other model of endotoxemia (induced by lethal dose of LPS), 0.9µmol/mouse 
decreased the serum TNF-α levels significantly to 454.5±33.49 pg/ml.
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Figure 3.21: Effect of aloe-emodin on TNF-α levels in endotoxemia. a) C57BL/6 
mice were pretreated (i.p. injection) with two doses of AE(0.9µmol/mouse and 1.3
µmol/mouse) for 1hr and endotoxemia was induced by sub-lethal doses of LPS 
(200ug/mouse) (i.p.), serum was collected after 4hr and used for cytokine analysis b)
C57BL/6 mice were pretreated (i.p. injection) with AE(0.9µmol/mouse) for 1hr and 
endotoxemia was induced by high doses of LPS (400ug/mouse) (i.p.), serum was 
collected after 4hr and used for cytokine analysis c) comparative effect of AE 
(0.9µmol/mouse) on TNF-α levels in two different endotoxemic mice.  The values are 
expressed in mean (±SEM) †, p< 0.001 when compared with control, *p < 0.05 and 
**p < 0.01 when compared with the groups treated with endotoxemic mice, n=5 in 
each group; p-values were calculated by Bonferroni non-parametric ANOVA test.
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IL-1 β
IL-1 is synthesized by mononuclear phagocytes, polymorphonuclear leucocytes and 
other cell types and affects a wide variety of tissues. IL-1β is the predominant form of 
this mediator produced by endotoxin-stimulated human monocytes and detected in the 
plasma of septic animals. IL-1β is increased in humans after infusion of endotoxin, 
although at lower concentrations than TNF-α. Like TNF-α, IL- 1β activates the 
production of other cytokines, including IL-6, IL-8 and TNF-α. Some studies have 
shown a direct correlation of survival rates of septic patients with serum IL-1β levels. 
IL-1β levels peak at 4hr in septic models. We checked the effect of aloe-emodin on 
serum levels of IL-1β at this peak concentration. IL-1β levels in serum were low in 
both vehicle control (11.40±1.134 pg/ml) and drug control (13.04±1.617 pg/ml).  At 
4hr after LPS (200 µg) infusion, serum IL-1β increased to 341.1±21.13 pg/ml 
significantly compared to controls. Pretreatment of aloe-emodin for 1hr attenuated the 
rise in IL-1β levels significantly, however 0.9µmol/mouse (163.2 ±10.39 pg/ml) 
decreased the levels more than 1.3µmol/mouse (272.9±17.24 pg/ml). In other LPS 
induced endotoxemic mice model (400µg), IL-1β showed significant increase 
(456.6±39.91 pg/ml) compared to control groups and aloe-emodin (0.9µmol/mouse) 
pretreatment induced marked suppression in this increase (209.3±35.32 pg/ml).
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Figure 3.22: Effect of aloe-emodin on IL-1β levels in endotoxemia. a) C57BL/6 
mice were pretreated (i.p. injection) with two doses of AE(0.9µmol/mouse and 1.3
µmol/mouse) for 1hr and endotoxemia was induced by sub-lethal doses of LPS 
(200ug/mouse) (i.p.), b) C57BL/6 mice were pretreated (i.p. injection) with 
AE(0.9µmol/mouse) for 1hr and endotoxemia was induced by high doses of LPS 
(400ug/mouse) (i.p.). Serum was collected after 4hr and used for cytokine analysis c) 
comparative effect of AE (0.9µmol/mouse) on IL-1β levels in two different 
endotoxemic mice.  The values are expressed in mean (±SEM) †, p< 0.001 when 
compared with control, *p < 0.05 and **p < 0.01 when compared with the groups 
treated with endotoxemic mice, n=5 in each group; p-values were calculated by 
Bonferroni non-parametric ANOVA test.
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IL-6
IL-6 is a 21-kDa glycoprotein produced by many cell types, including lymphocytes, 
fibroblasts and monocytes. IL-6 has a variety of biological effects, including 
activation of B- and T-lymphocytes, induction of acute phase protein production in 
the liver, and modulation of haematopoiesis. In addition, IL-6 can activate the 
coagulation system and function as a pyrogen. In vitro, IL-6 suppresses the production 
of TNF-α and IL-1β. The exact role of IL-6 in sepsis is uncertain.
We checked the effect of aloe-emodin on IL-6 levels in endotoxemic mice. It was 
seen after 4hr, IL-6 levels were raised (183.4±6.139 pg/ml) significantly compared to 
control group (6.141±2.268 pg/ml), however pretreatment with aloe-emodin for 1hr 
did not affect the levels significantly (166.3±6.885 pg/ml).
Figure 3.23: Effect of aloe-emodin on IL-6 levels in endotoxemia. C57BL/6 mice 
were pretreated (i.p. injection) with AE(0.9µmol/mouse) for 1hr and lethal 
endotoxemia was induced by high doses of LPS (400ug/mouse) (i.p.), serum was 
collected after 4hr and used for cytokine analysis. The values are expressed in mean 
(±SEM) †, p< 0.001 when compared with control, *p < 0.05 and **p < 0.01 when 
compared with the groups treated with endotoxemic mice, n=5 in each group; p-
values were calculated by Bonferroni non-parametric ANOVA test.
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Multiple organ dysfunction 
Organ dysfunction is a hallmark of severe sepsis. There is a close relationship 
between the severity of organ dysfunction on admission to an ICU and the probability 
of survival and between the numbers of organs failing and the risk of death. To 
analyse the effect of aloe-emodin on liver, kidney, lung dysfunction in endotoxemia, 
lethal dose of LPS (400µg/mouse) was administred (i.p.) 1hour after aloe-emodin 
(0.9µmol/mouse) treatment.
3.20 Effect of aloe-emodin on liver injury in endotoxemia
The liver is a central regulator of the systemic immune response following acute 
traumatic or surgical insult. It is the primary site for clearance of bacterial endotoxin, 
so is also subject to injury and dysfunction during sepsis. Liver involvement in sepsis 
is common and characterized by either hepatitis like injury or a mixed, hepatic and 
cholestatic, pattern of injury. In endotoxemia and sepsis patients have also been seen 
to have abnormal liver biochemistry. To assess the effect of aloe-emodin on liver 
injury, histopathological studies and serum profile for liver injury were checked.
3.20.1 Liver Histopathology
Mice from control, endotoxemic and treated groups were sacrificed after 18h of LPS 
administration. Histological evaluation was done of liver tissue sections from all three 
groups. Histological evaluation revealed endotoxemia-induced liver injury with 
parenchymal necrosis, parenchymal infarction, sinusoidal dilatation, perivenular 
inflammation, ductular cholestasis and parenchymal infilitration by inflammatory 
cells in endotoxemic mice. No apparent changes were observed in tissue sections 
obtained from vehicle control and drug control mice. Pre-treatment of aloe-emodin 
was seen to decrease the severity of liver injury significantly, as revealed by 
hematoxylin & eosin staining (overall score) (p<0.05) (Fig 3.24).
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Figure 3.24: Effect of aloe-emodin on liver histopathology in endotoxemia. Mice 
were pretreated (i.p. injection) with AE (0.9µmol/mouse) for 1hr and lethal
endotoxemia was induced by lethal doses of LPS (i.p.). Mice were sacrificed after 
18hr and liver from all three groups were harvested and stained with H/E [Normal (a 
& b), endotoxemic (c & d), treated (e & f)]. The overall pathology score sum of six 
fields (g) showed improvement (left,*p<0.05).
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3.20.2 Clinical Data
Liver-related biochemical patterns were checked in all the groups of mice at 18hr 
after LPS treatment. Endotoxemic mice showed a significant rise in liver damage 
markers i.e., alkaline phosphate (ALP) and alanine amino-transferase (ALT)
compared to control group and pretreatment with aloe-emodin resulted in significant 
decrease in ALT levels but not ALP (serum ALT: vehicle control, 59±13.40 U/L; AE 
only, 61.67±21.11 U/L; LPS only, 273±41.24 U/L; LPS+AE, ± 135±21.39 U/L: 
serum ALP: vehicle control, 12±0.91 U/L; AE only, 20±8.83 U/L; LPS only, 
120.8±15.02 U/L; LPS+AE, 70.67±41.70 U/L ). Decrease in ALT levels, suggest that 
aloe-emodin decreases the hepato-cellular damage in liver.
Figure 3.25: Effect of aloe-emodin on liver function in endotoxemia. Mice were 
pretreated (i.p. injection) with AE (0.9µmol/mouse) for 1hr and lethal endotoxemia 
was induced by high doses of LPS (400µg/mouse) (i.p.), serum was collected 18hr 
after LPS injection and assayed for ALT and ALP. The values are expressed as mean 
(±SEM) †, p< 0.001 when compared with control, *p < 0.05 and **p < 0.01 when 
compared with the groups treated with endotoxemic mice, n=5 in each group; p-
values were calculated by Bonferroni non-parametric ANOVA test.
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3.21 Effect of aloe-emodin on kidney injury in endotoxemia
Development of acute renal failure during sepsis syndrome is common and portends a 
poor outcome. The interplay between systemic host responses, local insults in the 
kidney, immune system and vascular bed, all play a role in the development of 
sepsis-induced acute renal failure. Despite recent advances in critical care, mortality 
rates in septic patients remained high for sepsis-associated acute renal failure. 
3.21.1 Histopathology
Histological evaluation revealed endotoxemia-induced kidney injury with interstitial 
oedema with separation of tubules, tubular cell swelling, shedding of tubule cells, 
interstitial inflammation, perivascular/interstitial lymphoid and  myeloid cells, 
vascular Congestion, glomerular infilitration in endotoxemic mice. No apparent
changes were observed in tissue sections obtained from vehicle control and drug 
control mice. Pre-treatment with aloe-emodin decreased the overall kidney injury as 
implicated by total histopathology score compared to endotoxemic mice (p<0.005) 
and significant attenuation was seen in inflammation induced swelling, accumulation 
of perivascular/interstitial lymphoid and myeloid cells and also glomerular 
infilitration (Fig 3.26).
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Figure 3.26: Effect of aloe-emodin on kidney histopathology in endotoxemia. 
Mice were pretreated (i.p. injection) with AE (0.9µmol/mouse) for 1hr and lethal
endotoxemia was induced by lethal doses of LPS (i.p.). Mice were sacrificed after 
18hr and kidneys from all groups were harvested and stained with H&E [Normal (a & 
b), endotoxemic (c & d), treated (e & f)]. The overall pathology score sum of six 
fields (g) showed improvement (left,*p<0.05).
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3.21.2 Clinical Data
Following LPS infusion mice developed a comparable acute renal failure (ARF) with 
elevated levels of BUN and creatinine compared to control mice after 18hr. 
Pretreatment with aloe-emodin resulted in significant decrease in both these 
parameters (serum creatinine: vehicle control, 0.107±0.027 mg/dl; AE only, 
0.107±0.024 mg/dl; LPS only, 0.513±0.031 mg/dl; LPS+AE, ± 0.143±0.073 mg/dl: 
serum BUN: vehicle control, 113±11.69 mg/dl; AE only, 123.1±15.07 mg/dl; LPS 
only, 578±14.88 mg/dl; LPS+AE, 328.1±59.84 mg/dl). 
Figure 3.27: Effect of aloe-emodin on kidney function in endotoxemia. Mice were 
pretreated (i.p. injection) with aloe-emodin (0.9µmol/mouse) for 1hr and lethal 
endotoxemia was induced by high doses of LPS (400µg/mouse) (i.p.), serum was 
collected at 18hr after LPS injection and assayed for BUN and Creatinine. The values 
are expressed in mean (±SEM) †, p< 0.001 when compared with control, *p < 0.05 
and **p < 0.01 when compared with the groups treated with endotoxemic mice, n=5 
in each group; p-values were calculated by Bonferroni non-parametric ANOVA test.
Results
94
3.22 Effect of aloe-emodin treatment on ALI in endotoxemia
The lung is the most frequently failing organ in sepsis as the increased metabolic rate 
associated with sepsis necessitates a high minute volume requirement. Inflammatory 
and oxidative damage to alveolar epithelial cell and microvascular endothelium leads 
to changes in pulmonary structure and function that characterize acute lung injury 
(ALI).
3.22.1 Histopathology
LPS injection (leading to endotoxemia) resulted in severe lung injury as observed in 
tissue sections of mice which were sacrificed after 18hrs. Endotoxemic mice tissues 
showed alveolar collapse, hemorrhage, and edema, neutrophil accumulation, intra-
septal lymphocytic inflammation, intra-alveolar inflammation,   peribronchi/
perivascular inflammation. The aloe-emodin pretreatment significantly decreased the 
overall score in mice lungs compared to endotoxemic mice, decreasing the 
inflammation mediated alveolar collapse, intra-septal and intra-alveolar inflammation 
and also peribronchi/perivascular inflammation. 
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Figure 3.28: Effect of aloe-emodin on lung histopathology in endotoxemia. Mice 
were pretreated (i.p. injection) with aloe-emodin (0.9µmol/mouse) for 1hr and lethal
endotoxemia was induced by lethal doses of LPS (i.p.). Mice were sacrificed after 
18hr and lungs from all groups were harvested and stained with H/E [Normal (a & b), 
endotoxemic (c & d), treated (e & f)]. The overall pathology score sum of six fields 
(g) showed improvement  (left,*p<0.05).
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3.22.2 Neutrophil Infiltration 
Endotoxin administration or sepsis produce acute inflammatory lung injury (ALI). 
ALI is characterized by the accumulation of large numbers of neutrophils into the 
lungs and a pulmonary inflammatory response in which there is increased production 
of immunoregulatory cytokines. Neutrophil infiltration in lungs of endotoxemic mice
was confirmed by myeloperoxidase (MPO) assay, which is an indirect marker for 
neutrophil presence.  As compared with control mice, endotoxemic mice tissues had a 
significantly greater level of lung MPO and aloe-emodin treatment decreased the 
levels significantly (p<0.05).
Figure 3.29: Effect of aloe-emodin on myeloperoxidase levels in lung tissues. 
Mice were pretreated (i.p. injection) with aloe-emodin (0.9µmol/mouse) for 1hr and 
lethal endotoxemia was induced by high doses of LPS (400µg/mouse) (i.p.). Mice 
were sacrificed after 18 h and lungs from all groups harvested and tissue homogenate 
assayed for MPO. The assay was expressed in percentage with LPS group referring to
100%.  The values are expressed as mean (±SEM) †, p< 0.001 when compared with 
control, **p < 0.01 when compared with the groups treated with endotoxemic mice, 
n=5 in each group; p-values were calculated by Bonferroni non-parametric ANOVA 
test.
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TNF-α
Accumulation of neutrophils in lung tissues results in acute inflammation in lung 
tissues.  Neutrophils express proinflammatory cytokines, including IL-1α, IL-1β, IL-
8, and TNF-α. TNF-α, which is said to be main mediator of organ damage, was 
analysed in lung tissues from different mice groups at 18hr after LPS injection. 
Compared with lung tissues from control group, TNF-α level were markedly high in 
endotoxemic mice (vehicle control, 6.88±2.2 pg/ml: AE only, 10.06±0.7492 pg/ml: 
LPS, 101.7±17.46 pg/ml), however the aloe-emodin treatment significantly attenuated 
this increase (LPS +AE, 40.05±3.36 pg/ml). 
Figure 3.30: Effect of aloe-emodin on TNF-α levels in lung tissues. Mice were 
pretreated (i.p. injection) with AE (0.9µmol/mouse) for 1hr and lethal endotoxemia 
was induced by high doses of LPS (400µg/mouse) (i.p.). Mice were sacrificed after 18 
h and lungs from all groups harvested and tissue homogenate assayed by ELISA. The 
values are expressed in mean (±SEM) †, p< 0.001 when compared with control, **p < 
0.01 when compared with the groups treated with endotoxemic mice, n=5 in each 
group; p-values were calculated by Bonferroni non-parametric ANOVA test.
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Sepsis is the tenth leading cause of death. Most of sepsis cases (40 percent) are fatal, 
and in most cases, the resulting multi organ failure and not the basic underlying 
infection, is the primary or main cause of death. Sepsis describes a complex clinical 
syndrome that develops when initial, appropriate host response to an infection 
becomes amplified and then dysregulated. Sepsis can be caused by infection with 
Gram-negative bacteria, Gram-positive bacteria, fungi, or viruses. Sepsis may also 
occur in the absence of detectable bacterial invasion, which include, microbial toxins
(exo or endo), particularly Gram-negative bacterial endotoxin (LPS) and endogenous 
cytokine production have been implicated as mediators and initiators (Hardaway, 
2000; Wheeler and Bernard, 1999).  
Many features of local and systemic inflammation can be mimicked by administration 
of LPS i.e., endotoxemia. LPS is capable of selective activation of a class of 
macrophages through an elaborate series of events (Aderem and Ulevitch, 2000; 
Martins et al., 2006; Wright et al., 1990). Toll like receptors (TLRs) initiate a 
casacade of intracellular signaling activating various kinases e.g. PKC, MAPK, SRC 
resulting in the activation of pro-inflammatory transcription factors such as activator 
protein-1 (AP-1), nuclear factor kappa B (NF-κB), and interferon response factor-3 
(IRF-3), leading to the production of pro-inflammatory chemokines, cytokines and 
nitric oxide (Beutler, 2004). 
Cytokines are  key elements in the inflammatory response that characterizes sepsis 
and septic shock. Two types of cytokines are released: proinflammatory (which 
include early such as tumor necrosis factor-α [TNF-α], IL-1β and IL-8 and late 
HMGB1) and anti-inflammatory (such as IL-10).TNF-α is one of the most important 
cytokines involved in the pathophysiology of sepsis and is released early in the 
process of sepsis. TNF-α induced tissue injury is largely mediated through neutrophils 
that respond by producing elastase, superoxide ion, sPLA2, hydrogen peroxide, 
platelet-activating factor (PAF), thromboxane A2 and leukotriene B4,. In addition, 
TNF-α amplifies inflammatory cascades in an autocrine and paracrine manner by 
activating macrophages/monocytes to secrete other pro-inflammatory cytokines 
(Calandra et al., 2002; Herbertson et al., 1995). IL-1β stimulates the synthesis and 
release of prostaglandins, elastases, and collagenases. It promotes transendothelial 
migration of neutrophils, and activates endothelial microvascular cells, which respond 
Discussion 
101
by releasing PAF and IL-8 (both of which are powerful neutrophil-stimulating agents)
(Curfs et al., 1997). TNF and other proinflammatory cytokines (like IFN- γ) stimulate 
macrophages to release HMGB1 (Ivanov et al., 2007; Wang et al., 1999). HMGB1 is 
also released by macrophages when stimulated directly by exogenous bacterial 
products (such as endotoxin or CpG-DNA) (Rendon-Mitchell et al., 2003; Tang et al., 
2007). HMGB1 is now perceived to be a major mediator of prolonged and sustained 
inflammation in sepsis, since it is released about 16hrs after early cytokines and its 
level remain high for several days (Chen et al., 2004; Jiang et al., 2007; Tang et al., 
2005). Animals exposed to high levels of recombinant HMGB1 develop a sickness 
syndrome characterized by piloerection, decreased mobility, increased somnolence, 
weight loss and fever similar to sepsis syndrome. 
Despite the extraordinary developments in understanding the immunopathology and 
pathobiology of sepsis, therapeutic advances have been drastically slow. Currently, 
available strategies for the management of sepsis patients include: rapid identification 
of causative organisms; timely patient identification and diagnosis; improved 
ventilatory techniques (low-pressure ventilation); appropriate, timely antimicrobial 
therapy; appropriate (goal-directed) haemodynamic support; targeted pharmacological 
therapies (recombinant activated protein C) immunological therapy and glycaemic 
control (intensive insulin therapy); effective supportive therapies (prophylaxis against 
stress ulcers, administration of anticoagulants and dialysis); appropriate nutrition; and 
patient management by highly qualified clinicians, techniques and nursing staff 
(Bollaert et al., 1998; Bone et al., 1992; Briegel et al., 1994; Ibrahim et al., 2008; 
Martins et al., 2006; Natanson et al., 1998; Rivers et al., 2001; Wheeler and Bernard, 
1999; Zhang et al., 1995). These strategies have helped to reduce the support failing 
organs, incidence of infections, and prevent complications (Rivers et al., 2001). But 
these measures require whole-hearted involvement of the entire healthcare team and 
the provision of strong support in achieving these objectives cannot be stressed 
enough. So presently the focus is to find better drugs to combat disease and curb it at 
initial stages.
Development of drotrecogin alfa (activated), which is a recombinant version 
of activated protein C (APC), for sepsis therapy created big hopes. It was developed 
by Eli Lilly and Company and is marketed under the brand name Xigris. Activated 
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protein C has profound anti-apoptotic & anti-inflammatory properties, in addition to 
its anticoagulant activity. However APC was found to have its own complications in 
ADDRESS (Administration of Drotrecogin alfa (activated) in Early Stage Severe 
Sepsis) trial.
A series of antilipopolysaccharide treatment strategies for sepsis have been done for 
more than 20 years, including antiendotoxin antibodies, lipid A (harboring the LPS 
biological activity) antagonists, polymixinB, extracorporeal endotoxin absorber, 
bactericidal /permeability-increasing protein, cathelicidins, limulus 
antilipopolysaccharide factor and lactoferrin. These therapeutic agents have 
demonstrated efficacy in animal research, however, numerous attempts to neutralize 
LPS in clinical trials in septic patients have proven ineffective (Nahra and Dellinger, 
2008). TLR4 antagonists (like E5564 and TAK-242) were also developed to curb 
sepsis menace, however they too provided no respite (Leon et al., 2008). 
HMGB1 levels in serum remains high days after actual insult giving a wide 
therapeutic window for therapy compared to other cytokines. It is speculated that 
agents capable of decreasing HMGB1 release might prove as potential candidates for 
sepsis therapy (Sappington et al., 2003). This study was undertaken to identify novel 
compound targeting HMGB1 and further elucidating its role in sepsis/ endotoxemia. 
Since HMGB1 is released in both processes i.e., apoptosis and necrosis (Raucci et al., 
2007; Tang et al., 2010) so we needed to assess non toxic doses of test compounds for 
macrophage cells. Any kind of stress would change the distribution of cellular 
HMGB1. Non toxic doses of all the test compounds were used keeping this in mind 
same is depicted in the results under viability assay (Fig 3.1).
Screening of test compounds
Based on HMGB1 release it would be cumbersome to screen many compound so we 
screened compounds on the basis of their nitric oxide (NO) scavenging potential in 
activated macrophages. During the course of sepsis, increased amounts of nitric oxide 
levels are produced, and elevated levels of nitric oxide metabolites in patients with 
sepsis have been correlated with LPS or endotoxin levels and with organ-failure 
scores (Gomez-Jimenez et al., 1995; Groeneveld et al., 1996). 
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Statins are reported to greatly reduce the leucocytes migration and leucocytes 
recruitment induced by lipopolysaccharide (LPS) (Diomede et al., 2001; Pruefer et 
al., 2002). Statins reduce leucocytes adhesion to endothelium by down-regulating 
surface expression of endothelial cell adhesion molecule (ECAMs): P-selectin, 
CD11b, and CD18 (Weber et al., 1997; Yoshida et al., 2001). Statins have also seen 
to affect the production of many acute phase reactants, such as TNF-α, IL-8, IL-6, 
monocyte chemoattractant protein-1 (MCP–1), and C-reactive protein (CRP) (Albert
et al., 2001; Arnaud et al., 2005; Musial et al., 2001). Many statins are reported to 
have beneficial role in sepsis, we studied effect of rosuvastatin (a synthetic statin) in 
endotoxin induced inflammation in RAW 264.7 macrophages cells. Rosuvastatin did 
not showed any significant downregulation on LPS induced NO in RAW 264.7 cells
(Fig 3.3).
Crocus extracts (Crocus sativus L. (Iridaceae) are reported to process anti-
inflammatory and immunomodulatory actions (Hosseinzadeh and Sadeghnia, 2005; 
Kianbakht and Ghazavi, 2011). One of the main components of crocus extracts is 
safranal which is shown to have high antioxidant and free radical scavenging activity 
(Hosseinzadeh and Sadeghnia, 2005). Safranal did not show any effect on LPS  
induced NO generation, which was confirmed by iNOS expression (Fig 3.4). 
Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) is an anthraquinone derivative 
from the rhizome of Rheum palmatum, an herb widely used as a laxative in traditional 
Chinese medicine (Shi et al., 2001). It has been reported that emodin possesses a 
variety of biological activities, such as vasorelaxative (Huang et al., 1991), 
immunosuppressive (Kuo et al., 2001), hepatoprotective (Lin et al., 1996), and anti-
tumor activity (Shi et al., 2001; Chang et al., 1996). Treatment of RAW 264.7 
macrophages with emodin (20 µg/ml) inhibited the expression of a panel of 
inflammatory-associated genes, including TNF-α, iNOS, interleukin-10 (IL-10), 
cytosolic inhibitor of κB (IκB)α, IκB kinase (IKK)-α and IKK-γ, and the nuclear 
translocation of nuclear factor-κB (NF-κB) (Li et al., 2005).  Our study showed 
significant inhibition of LPS induced NO by emodin (Fig 3.4). Since effect of emodin
on HMGB1 in macrophages were reported during the course of study, so we did not 
pursue its use further (Chen et al., 2010).
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Effect of psychosine on inflammatory mediators in RAW 264.7 cells and 
peritoneal macrophages
Galactosyl sphingosine (Psychosine) is abnormally increased in brain in a disease 
known as Krabbe disease. Psychosine accumulation is believed to be the primary 
cause of the rapid degeneration of the myelin-forming cells and consequent 
demyelination that is seen in this disease (Miyatake and Suzuki, 1972). The 
mechanisms by which psychosine mediates cell death is unclear yet. In Krabbe 
disease the microglial cells are activated which become phagocytic and secrete a 
variety of cytokines, including the proinflammatory cytokines, TNF-α, interleukin 1-
beta and interferon-gamma. These cytokines perpetuate and augment microgliosis as 
well as induce glial cells and astrocytes to become hypertrophic and undergo reactive 
astrocytosis (Merrill and Benveniste, 1996). The role of psychosine outside neuronal 
system is poorly studied.   In addition effect of psychosine on different cell types 
varies considerably, however effect on RAW 264.7 cells has not been seen yet. 
We observed that psychosine showed different response in RAW 264.7 cells and 
primary peritoneal macrophages. The results were in concordance with earlier reports 
of psychosine showing different response in different cells depending upon origin of 
cell line (glial cell line vs primary mixed gial cells) (Bashir and Haq, 2011). The 
primary peritoneal macrophages is mixed in nature including primarily macrophages 
and specific B cell subsets, thus probably explaining the variation in response of 
psychosine in two.
In LPS stimulated RAW 264.7 cells, psychosine showed decrease in NO and TNF-α 
level but no change in levels of HMGB1 was seen. On the other side, in activated 
peritoneal macrophages, psychosine showed a significant increase in LPS-induced 
NO, TNF-α, along with HMGB1. The psychosine induced significant release of 
HMGB1 levels in primary peritoneal macrophages even in the absence of LPS.  It has 
already been reported that psychosine potentiates the LPS-induced expression of 
iNOS and the production of proinflammatory cytokines (IL-1β, TNF-α, and IL-6)
production in rat primary astrocytes (Giri et al., 2002). Psychosine is said to cause 
apoptotic mediated death of oligodendrocytes (Haq et al., 2003; Zaka and Wenger, 
2004). As HMGB1 is released in apoptotic death and also mediates the inflammatory 
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response in later stages. Thus increase in HMGB1 release by psychosine might be one 
of mediators of psychosine induced lethality. However we used low doses of 
psychosine which had no effect on RAW 264.7 cell viability (Fig 3.1) so it is 
proposed that psychosine mediated HMGB1 release in peritoneal macrophages is not 
because of apopotosis or necrosis but a different pathway may be involved. Based on 
the known literature, it can be proposed that, psychosine at low levels may result in 
activation of cells releasing HMGB1 which surge inflammation and later mediate 
inflammation and apoptosis (Galbiati et al., 2007; Galbiati et al., 2009). However,
further studies need to check the actual role of HMGB1 in Krabbe disease.
Effect of aloe-emodin on inflammatory mediators in RAW 264.7 cells and 
peritoneal macrophages
Aloe-emodin (AE), a hydroxyanthraquinone naturally present in the leaves of Aloe 
vera (Dutta et al., 2007), has antiviral, antimicrobial and hepatoprotective activities 
(Arosio et al., 2000; Eshun and He, 2004)  and anticancer activity in neuroectodermal 
tumors (Pecere et al., 2000), lung squamous cell carcinoma (Lee, 2001), hepatoma 
cells (Kuo et al., 2002) and in  glial cell line (Acevedo-Duncan et al., 2004). Studies 
have shown aloe-emodin as antioxidant under various stress. However aloe-emodin 
role in LPS induced inflammation has not yet been studied. 
During this study we found aloe-emodin decreased LPS induced NO production and 
iNOS expression dose dependently (Fig 3.7). Similar dose dependent effect was seen 
on LPS induced extra-cellular release of HMGB1 in RAW 264.7 macrophages and 
primary peritoneal macrophage cells (Fig 3.13 & 3.14). On LPS stimulation HMGB1 
is first translocated from nucleus to cytoplasm and then outside the cells. Aloe-
emodin was seen to partially decrease the nuclear to cytoplasmic translocation of 
HMGB1 (Fig 3.15). 
The pro-inflammatory cytokines i.e., TNF-α, IL-1β are released much early than 
HMGB1 and mediate early inflammatory damage on stimulation with LPS. The drugs 
which inhibit pro-inflammatory cytokines both early cytokines (TNF, IL-1) and late 
cytokines (HMGB1) are seen as good candidate for sepsis/endotoxemia therapy. The 
aloe-emodin treatment inhibited both TNF-α, IL-1β in dose dependent manner in 
RAW 264.7 cells with 15µM decreasing the levels most (Fig 3.17 & 3.18). However 
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in peritoneal macrophages the pattern of inhibition of TNF-α and IL-1β is different. 
Aloe-emodin inhibited the TNF dose dependently in peritoneal macrophages, but IL-
1β inhibition showed different pattern with maximum inhibition at 10µM. 
In response to oxidative stress, macrophages also induce heme-oxygenase 1 (HO-1), 
which has protective effect in innate immune cells and exerts anti-inflammatory 
effects that limit the damaging consequences of inflammation and immunity 
(Otterbein et al., 2003; Wagener et al., 2003).   Aloe-emodin increased the LPS 
induced HO-1 expression in RAW 264.7 cells (Fig 3.19). Recent studies proved a 
close relationship between HO-1 and HMGB1 in inflammatory conditions (Tsoyi et 
al., 2009). HO-1 has been reported to down regulate HMGB1 release via carbon 
monoxide in activated macrophages (Tsoyi et al., 2009). Up-regulation of HO-1 is 
seen to protect mice from the lethal effect of LPS- and CLP-induced sepsis, paralleled 
by a decrease in the systemic levels of HMGB1.  Thus HO-1 may be involved in aloe-
emodin mediated HMGB1 inhibition.
Drugs inhibiting HMGB1 are seen as good targets for sepsis therapy. Efficacy of aloe-
emodin against sepsis was tested in mice model of endotoxemia. It was observed that 
aloe-emodin protected the mice in both sub-lethal and lethal model of endotoxemia. 
The survival was seen more in mice administered with aloe-emodin at the dosage of 
0.9μg/mouse (Fig 3.20). 
Proinflammatory cytokines are major players in sepsis lethality and among the 
cytokines involved in endotoxic shock, TNF-α appears to play a central role. Indeed, 
increased serum TNF-α levels appear during endotoxemia and TNF-α injection 
induces shock, tissue damage, and death (Tracey et al., 1986). During endotoxic 
shock, TNFα shows a large spectrum of harmful effects. These effects include 
increase in procoagulant activity of vascular endothelial cells, activation of 
macrophages and neutrophils, and increase in combination with IFNγ in the 
expression of adherent molecules resulting in increased neutrophil/monocyte 
adherence to endothelial cells and tissue infiltration. Aloe-emodin decreased the 
levels of proinflammatory cytokines i.e., TNF-α and IL-1β (Fig 3.21 &3.22). The
pattern of inhibition however varies in case of TNF-α and IL-1β indicating pleiotropic 
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actions of aloe-emodin. Aloe-emodin treatment at both high and low doses showed 
no effect on IL-6 levels in endotoxemic mice (Fig 3.23). 
TNFα in early stages and HMGB1 in later stages mediates neutrophil and macrophage 
accumulation which damages the organs, thereby causing multi-organ dysfunction 
syndrome (MODS). Treatment with aloe-emodin protected endotoxemic mice from 
organ dysfunction as seen by serum biochemistries (LFT and KFT) checked 18hrs 
after LPS administration (Fig 3.25 & 3.27). Protective effect of aloe-emodin was also 
observed in histopathology study of liver, kidney and lung sections analysed by H&E 
staining.  Treatment with aloe-emodin shows improved organ histology compared to 
endotoxemic mice (Fig 3.24, 3.26 & 3.28). Histopathology showed significant 
decrease in neutrophil infilitration in lung tissue sections compared to endotoxemic 
mice. Neutrophil infiltration and high level of cytokine in lungs leads to acute lung 
injury (ALI), which is an early characteristic of multiple organ dysfunction and is 
responsible for high mortality and poor prognosis in patients with sepsis [Ware,
2000]. In this present study, the levels of both TNF and neutrophils increased in 
endotoxemic mice even after 18hrs of LPS administration. Aloe-emodin was observed 
to inhibit both release of TNF and levels of neutrophils in lung tissues compared to 
endotoxemic mice (Fig 3.29 & 3.30).
This study can serve as a model to evaluate the mechanism of aloe-emodin mediating 
inhibition of HMGB1 and its effect in other septic models like cecal ligation and 
puncture (CLP).
Thus, the results of present study clearly reveal that the aleo-emodin has potential to 
ameliorate HMGB1 release under inflammatory stress and also to decrease the level 
of proinflammatory cytokines and oxidative stress markers. Aloe-emodin showed good 
immunotherapeutic potential in LPS induced endotoxemic murine model of sepsis. 
The present study provides the basis for the future evaluation of aloe-emodin as a 
potential adjunct to the already existing sepsis therapy.
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 Aloe-emodin inhibited HMGB1 release in activated macrophage cells, by 
inhibiting LPS induced HMGB1 translocation from nucleus to cytoplasm.
 Aloe-emodin decreased the release of LPS-induced pro-inflammatory 
cytokines (TNF-α, IL-1β) in activated macrophages.
 Aloe-emodin decreased the acute inflammation induced stress markers NO, 
iNOS, HO-1 which may be a mechanism of HMGB1 regulation.
 Aloe-emodin protected mice from endotoxemic lethality.
 Aloe-emodin decreased the LPS induced proinflammatory cytokines (TNF-α, 
IL-1β) in mice at early hours of onset of disease.
 Aloe-emodin decreased the organ dysfunction (liver, kidney, lung) as seen by 
serum markers and histopathology study.
 Aloe-emodin decreased neutrophil infiltration and proinflammatory cytokine 
(TNF-α) in lungs.
 Psychosine showed different effect on LPS-induced inflammatory mediators 
depending on nature of cell.
 Effects on primary peritoneal macrophages resemble the in-vivo pathobiology 
of psychosine which hints a possibility of major role of HMGB1 in psychosine 
induced Krabbe disease.
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